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Allogeneic haematopoietic stem cell transplant (HSCT) remains the only curative therapy for 
many malignant and non-malignant diseases. Its use, however, remains limited by the 
morbidity and mortality caused by graft versus host disease (GVHD). Treatment options, even 
where successful, often further immunosuppress the recipient and potentially reduce the 
effectiveness of the transplant. 
 
IL-22, a member of the IL-10 family of cytokines, is an exciting potential therapy. Its receptor 
is found on the key target tissues of graft versus host disease, but not on leucocytes, thereby 
potentially separating GVHD from the graft versus tumour effect. The role of IL-22 in 
GVHD, however, remains controversial. Innate lymphoid cells (ILCs), found at many of the 
body’s barrier surfaces, have been shown to be key producers of IL-22, but knowledge of 
their function in human GVHD is limited.  
 
This project has further explored the role of IL-22 and ILCs in human stem cell 
transplantation. ILCs were depleted from the peripheral blood by transplant conditioning, and 
were predominantly of donor origin by Day 28. No difference was demonstrated in ILC 
recovery between patients who did and did not develop acute GVHD. No evidence was found 
of IL-22 induction by conditioning therapy, either full or reduced intensity, in the serum or 
skin, but serum IL-22 concentration was increased in GVHD. In addition, an IL-22 
polymorphism study found a greater risk of death from GVHD where the donor had a ‘high 
IL-22 producer’ genotype. Finally rIL-22 was tested in a skin explant model of GVHD and 
supraphysiological concentrations of IL-22 reduced the GVHD Grade in 50% of experiments 
performed. 
 
This project has further elucidated the role of ILCs and IL-22 in human GVHD and supports 
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‘What do you regard as the main principle – the, shall I say, the basic idea which you keep 
before you when you are exercising the practice of your profession?’ 
 There was a pause while Andrew reflected desperately. At length, feeling he was 
spoiling all the good effect he had created, he blurted out: 
 ‘I suppose – I suppose I keep telling myself never to take anything for granted.’ 
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Chapter 1 Introduction 
 
1.1 Stem cell transplantation 
Stem cell transplantation, used primarily for the treatment of haematological disorders, can be 
performed using cells previously harvested from the patient (autologous) or an alternative 
donor, either related or unrelated (allogeneic). In the majority of clinical situations where 
autologous transplantation is performed, the aim is to allow the delivery of high doses of 
chemotherapy, from which the bone marrow might not be able recover, and then to ‘rescue’ 
the bone marrow by returning the previously harvested stem cells (Greb et al., 2008). The 
exception to this is where autologous transplant is used to treat autoimmune disease, which 
will be discussed further below.  
In allogeneic stem cell transplant, in addition to allowing high dose chemotherapy to be given, 
the aim is to allow engraftment of a new, healthy immune system, which can be harnessed to 
fight the disease for which the transplant was performed (Kolb, 2008). 
 
1.1.1 The transplant process 
The patient undergoes conditioning with chemotherapy (in some cases with the addition of 
radiotherapy) with the aim of eradicating disease, followed by stem cell infusion. In 
allogeneic transplantation, the conditioning will include immunosuppressive agents to avoid 
rejection of the graft (Gyurkocza and Sandmaier, 2014), and may involve T cell depletion 
(discussed in 1.2.4). Originally allogeneic transplant conditioning was always performed with 
full intensity, or myeloablative conditioning. As the importance of the immune response was 
better understood, however, reduced intensity regimens were developed, that have made 
transplantation available to a much broader range of patients. Due to the high risk of infection 
during the transplant, patients often remain in isolation while awaiting engraftment. 
 
1.1.2 Complications 
The biggest risk common to allogeneic and autologous transplantation is infection. The type 
of infections most commonly seen shifts depending on the stage post-transplant (van Burik 
and Weisdorf, 1999, Leather and Wingard, 2001), with bacterial infections predominating in 
the early, neutropenic phase, but the risk of viral infections (both primary infection and 
reactivation) remaining for many months post allogeneic transplant, especially where there is 
on-going treatment with immunosuppressive therapy. 
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In allogeneic transplantation, graft versus host disease (GVHD), where the graft mounts a 
response to its new host, presents a specific challenge. GVHD forms the basis of this project, 
and is discussed in more detail in section 1.2. 
 
1.1.3 Allogeneic stem cell transplantation 
Allogeneic haematopoietic stem cell transplantation (HSCT), pioneered in the 1950s and 
1960s, but entering more mainstream clinical practice in the 1970s, remains the only 
potentially curative therapy for many haematological malignancies and immunodeficiencies. 
The advent of new techniques for transplant conditioning and donor selection have increased 
the number of patients for whom allogeneic HSCT is a clinical option, with EBMT (European 
Society for Blood and Marrow Transplantation) reporting 15 717 allogeneic transplants 
registered in 2017 (EBMT Annual Report 2017).   
 
1.1.4 Challenges in clinical application 
The use of HSCT as a clinical option remains limited by the morbidity and mortality caused 
by GVHD (Wingard et al., 2011). A variety of alternatives for the prevention of GVHD, 
including T cell depletion and prophylactic immunosuppression are well established in 
clinical practice, but successful treatment of established GVHD remains limited, and a 
complete response to glucocorticoids is achieved in less than 50% of those requiring systemic 
treatment (Pidala and Anasetti, 2010).  In addition, use of glucocorticoids post-transplant 
results in an increased risk of infection in an already vulnerable patient group (Thursky et al., 
2004). An ability to reduce GVHD, while maintaining the graft versus leukaemia/graft versus 
tumour effect would potentially increase the clinical application of HSCT. 
 
1.2 Graft versus host disease  
Graft versus host disease remains a common and significant complication of HSCT. The 
reported incidence and severity of acute GVHD (aGVHD) vary widely, depending on a 
number of factors including conditioning intensity, use of T cell depletion, donor matching, 
stem cell source and prophylaxis, but has been reported to be as high as 80%. The prognosis 
is especially poor in steroid refractory GVHD (Martin et al., 1990, Weisdorf et al., 1990). The 
large number of agents trialled as second line therapy reflect the lack of a successful 
candidate (Pidala and Anasetti, 2010, Saliba et al., 2012). Originally termed ‘runt disease’, 
‘wasting disease’ or ‘secondary disease’ (Billingham et al., 1960, van et al., 1959, Barnes et 
al., 1962) where ‘primary disease’ referred to the radiation-induced aplasia seen in 
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transplanted mice, it was Billingham who proposed a triad of requirements for the 
development of GVHD (Billingham, 1966).  
• The graft must include cells that are immunologically competent  
• There must be antigens present in the recipient that are not present in the donor 
• The recipient must be unable to mount a response to reject the transplanted cells 
 
1.2.1 Definitions, staging, grading and management 
GVHD has classically been divided into acute (aGVHD) and chronic (cGVHD), where 
aGVHD occurred within the first 100 days after HSCT. Changes in methods of 
transplantation, however, have somewhat blurred this distinction, although the clinical 
findings themselves are often distinctive. For this reason, in 2005 the National Institutes of 
Health, proposed a new set of definitions (Filipovich et al., 2005): 
 
Classical acute: Occurring within 100 days of HSCT or donor lymphocyte infusion (DLI), 
only features of acute GVHD 
Persistent, recurrent or late-onset acute GVHD: Only features of acute GVHD, but occurring 
beyond 100 days of HSCT or DLI 
Classic chronic: Features of chronic GVHD only 
Overlap syndrome: Features of acute or chronic GVHD occurring together 
 
Acute GVHD principally affects three target organs, the skin, liver and gastrointestinal tract. 
Each organ is staged separately, and the scores combined to give an overall grade. The 
definitions, using the modified Glucksberg criteria, are shown below (Glucksberg et al., 1974, 
Przepiorka et al., 1995):  
 
 
Table 1.1 Staging of acute GVHD, according to the modified Glucksberg criteria 
 
Stage& Skin& Liver&(Bilirubin)& GI&(Diarrhoea)&
1" <25%"BSA" 34,50umo/L" >500"mL/24hrs"












Table 1.2 Grading of acute GVHD, according to the modified Glucksberg criteria 
  
The overall grade is important for research and transplant registry purposes to assess 
outcomes following HSCT, but is also used to guide treatment and prognosis in clinical 
practice. Grade I GVHD can usually be managed with optimisation of immunosuppressive 
agents and topical therapy, while Grade II or above will usually require systemic 
corticosteroids. Despite the advent of newer agents, corticosteroids remain first line therapy 
for GVHD. Complete response rates quoted differ from 20-70%, with worse responses seen in 
those with higher grades of GVHD. In patients who are steroid refractory, however, the 
outcome is very poor, with mortality rates of up to 80% (Pidala and Anasetti, 2010, Cesen 
Mazic et al., 2018, Luft et al., 2011). 
 
Chronic GVHD can affect many organ systems, and the features are often similar to those 
seen in auto-immune conditions. The underlying pathophysiology is thought be distinct from 
that of aGVHD, the focus of this project. The manifestations of cGVHD, therefore, are not 
discussed in detail here. 
 
1.2.2 Pathophysiology 
Almost 50 years after Billingham, Ferrara proposed a three-phase model of GVHD 
development (Ferrara et al., 2009), illustrated in Figure 1.1. In the first phase, damage to the 
host tissues by transplant conditioning and the underlying disease causes activation of antigen 
presenting cells, resulting in the production of danger signals. In response to this, in phase 
two, donor T cells proliferate and differentiate. Phase three is then an effector phase, which 





Grade& Skin& Liver& Gut&
I" Stage"1)2" 0" 0"
II" Stage"3"or" Stage"1"or" Stage"1"
III" )" Stage"2)3"or" Stage"2)4"
IV" Stage"4"or" Stage"4" )"
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Figure 1.1 The three phase model of GVHD. Transplant conditioning results in tissue damage, 
with the release of pro-inflammatory cytokines. This leads to activation of host antigen 
presenting cells, which in turn activate donor T cells. These then produce further effectors, 
resulting in tissue damage. Adapted from Ferrara et al., 2009.  
 
  
1.2.3 Transplant conditioning and graft versus host disease 
Transplant conditioning refers to the chemotherapy, with or without radiotherapy given to the 
patient prior to stem cell infusion, necessary both to prevent rejection of the graft and, in some 
cases, for treatment of the underlying disease. Early transplant regimens were all 
myeloablative, and included total body irradiation (TBI) with high dose chemotherapy 
(Thomas, 2000). It is classically believed that conditioning results in tissue damage, with the 
release of inflammatory cytokines including TNFα, IL-1β and IL-6 (Hill et al., 1997, Henden 
and Hill, 2015). Ferrara’s model, where the first phase is the result of conditioning-induced 
damage gives a rationale as to why full intensity conditioning has been observed to result in 
more severe GVHD than reduced intensity (Aoudjhane et al., 2005). The pathophysiology 
underlying aGVHD following reduced intensity conditioning (RIC) is less well understood 
than following myeloablative conditioning. It is believed, however, to be the result of a 
similar process, although the timing and key cytokines may be different (Mohty et al., 2005). 
It is worth noting that the presence of a cytokine storm as a result of conditioning has itself 
been challenged (Melenhorst et al., 2012). 
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1.2.4 T cell depletion 
The importance of donor T cells in the pathogenesis of GVHD has led to the development of 
multiple methods, both physical and immunological, of T cell depletion. Although this has 
been shown to reduce the incidence of acute and chronic GVHD, this comes with an increased 
risk of relapse and graft rejection (Marmont et al., 1991, Maraninchi et al., 1987). Different 
mechanisms to overcome this through more selective depletion exist in clinical practice. 
These include the use of αβ T cell depletion and CD34+ selection (Saad and Lamb, 2017). 
For the samples analysed in this thesis, where the transplant was performed with T cell 
depletion, the patients have all received immunological in vivo T cell depletion with either 
Alemtuzumab (Campath-1H) or anti-thymocyte globulin (ATG). These agents are discussed 
in more detail below. 
 
1.2.5 Alemtuzumab 
Alemtuzumab, or Campath-1H is a recombinant, humanised immunoglobulin G1 (IgG1) 
monoclonal antibody, which targets human cluster of differentiation marker (CD) 52, 
resulting (in vitro) in complement and antibody-dependent cell mediated cytotoxicity (Hu et 
al., 2009). CD52, a glycosylphosphatidylinositol (GPI) anchored glycoprotein is expressed by 
most B and T lymphocytes (both healthy and malignant)(Ginaldi et al., 1998), with lower 
expression being seen in NK (natural killer) cells. Some expression has also been 
demonstrated on monocytes, basophils and dendritic cells, but, in vitro at least, T and B 
lymphocytes appear the most susceptible to treatment with Alemtuzumab (Rao et al., 2012). 
CD52 is also expressed in the male reproductive tract, including the epididymis and on the 
surface of mature spermatozoa (Hale et al., 1993). The function of CD52 remains unclear, but 
there is some evidence to suggest it acts as a co-stimulatory molecule for T cells (Watanabe et 
al., 2006), and plays a role in their migration (Masuyama et al., 1999).  
 
The Campath antibodies (including CAMPATH-1M, CAMPATH-1G, and CAMPATH-1H) 
developed in Cambridge by Geoff Hale and Herman Waldmann (Riechmann et al., 1988, 
Bruggemann et al., 1987), showed initial clinical success in refractory non-Hodgkin 
lymphoma (Hale et al., 1988). Alemtuzumab is commonly used as part of the conditioning 
regimen for in vivo T cell depletion in allogeneic HSCT (in the United Kingdom). There is 
evidence for a reduction in both acute and chronic GVHD when Alemtuzumab is incorporated 
into the conditioning regimen (Kottaridis et al., 2000, Chakraverty et al., 2002). Not 
surprisingly, perhaps, this reduction in GVHD is accompanied by an increase in post-
transplant infections (Chakrabarti et al., 2002a, Perez-Simon et al., 2002, Chakrabarti et al., 
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2002b), slower immune reconstitution (Chakraverty et al., 2010, Morris et al., 2003) and an 
increase in mixed chimerism (Marsh et al., 2016). 
 
1.2.6 Antithymocyte globulin  
Antithymocyte globulin (ATG), purified immunoglobulin G is also commonly used for in 
vivo T cell depletion. The immunoglobulin is extracted from the sera of animals, usually 
rabbits or horses, which have been immunised using human thymocytes or the Jurkat cell line 
(similar to activated T cells). Unlike Alemtuzumab, ATG targets multiple antigens and 
various groups have investigated the likely functional targets (Mohty, 2007, Bonnefoy-Berard 
et al., 1991, Preville et al., 2001). The mechanism of action is believed to be through both the 
depletion of lymphocytes and interference with their functional surface molecules. The 
different products that are available are not identical, and findings from one should not be 
extrapolated to all.  
 
1.2.7 T regulatory cells 
While I have focused on the use of T cell depletion to reduce the incidence of GVHD, it is 
worth noting that several subsets of T cells exist. In addition to the activated effector cells 
discussed above, a subset of T cells, known as T regulatory cells, exist to control the immune 
response. Usually classified as CD4+CD25+Foxp3+, in 1995 it was shown in a murine model 
that these cells had the ability to transfer tolerance (Sakaguchi et al., 1995). The biology of T 
regulatory cells is beyond the scope of this thesis, but given their function, it is perhaps not 
surprising that trials of T regulatory cells for the prevention of GVHD have been performed, 
with some encouraging preliminary results (Di Ianni et al., 2011, Brunstein et al., 2011).  
 
1.2.8 Graft versus tumour effect 
One of the difficulties associated with the prophylaxis and treatment of GVHD is the potential 
loss of the associated graft versus tumour or graft versus leukaemia (GVT/GVL) effect. This 
effect, which is also reliant on donor T cells, is one of the key mechanisms by which 
allogeneic transplant exerts its anti-tumour effect, especially in the setting of reduced intensity 
conditioning. The increased risk of relapse seen with T cell depletion and the success of donor 
lymphocyte infusion, especially for conditions such as chronic myeloid leukaemia, have 
demonstrated the existence of GVL. Separation of GVL from GVHD, however, remains one 




1.3 Innate lymphoid cells 
Innate lymphoid cells (ILCs) are a population of cells, with lymphoid morphology but 
without lineage specific markers or rearranged antigen-specific receptors. They exhibit many 
functional parallels with T helper (Th) cells in relation to cytokine production. This is 
discussed further below.  
 
1.3.1 Innate versus adaptive immunity 
The human immune system employs a number of different mechanisms to protect us against 
infectious agents. Immunity can be broadly divided into the innate and adaptive immune 
systems, where the innate immune system is not changed by having previously encountered 
the organism and does not rely on specific recognition of the pathogen. It therefore provides 
the initial response, while the adaptive immune system has the ability to ‘remember’ and so 
respond more rapidly to a repeat infection (Chaplin, 2006).  
 
1.3.2 Innate immunity 
The innate immune system includes physical barriers, such as epithelium, a mucous layer or 
acidic or bactericidal fluids (such as gastric acid or tears). It is also responsible for the 
production of cytokines and chemokines to orchestrate a further response. The innate immune 
system recognises danger signals (e.g. pathogen-associated molecular patterns (PAMPs) such 
as lipopolysaccharides (LPS)), through toll-like receptors (TLRs) (Beutler et al., 2003), rather 
than recognising the pathogen itself and responds through mechanisms including 
phagocytosis by neutrophils or macrophages. Another key component of innate immunity is 
complement, which has also been shown to interact with the adaptive immune system 
(Morgan et al., 2005). Phagocytosis is enhanced by coating of the pathogen with C3b 
(complement system), which increases the adherence of the pathogen to the phagocytes 
through their receptors. Activation of the complement system also results in development of 
the membrane attack complex, which inserts directly into the pathogen leading to cell lysis 
(Serna et al., 2016). A further cellular component of the innate immune system is the innate 
lymphoid cell family. The so-called ‘helper ILCs’ are discussed in more detail below. NK 
cells, acting through non-specific receptors, recognise and kill virally infected host cells, by 
secreting perforin and granzyme (Yokoyama, 2005). 
 
1.3.3 Adaptive immunity 
In contrast to the innate immune system, adaptive immunity is specific for the antigen, and 
develops a memory for pathogens previously encountered (Chaplin, 2006). The two major 
 9 
subsets of cells are B (bone marrow derived) and T (thymus derived) lymphocytes. B cells 
each produce a unique antibody, which, when it binds its cognate antigen, results in 
differentiation to plasma cells, which continue producing the unique antibody, and memory B 
cells (Heesters et al., 2016). The antibody coats the pathogen, activating complement and 
enhancing phagocytosis. Both pre-existing antibodies and memory B cells, which are able to 
respond rapidly, form part of the immune response should the host be re-infected by the same 
pathogen (Kurosaki et al., 2015). An additional function of B cells is to present antigen to T 
cells through their MHC Class II. 
T cells have unique receptors for antigen recognition (the T cell receptor, or TCR). T helper 
cells (CD4+) recognise antigen on the cell surface of professional antibody presenting cells, 
such as dendritic cells, in combination with MHC class II. Providing there is appropriate co-
stimulation, this results in cytokine production by the T cell, that stimulates B cells to produce 
antibodies, in addition to other pro-inflammatory cytokines, thus further enhancing the 
immune response (Chaplin, 2006). Cytotoxic T cells (CD8+), in contrast recognise antigen in 
combination with MHC class I on infected cells. In both cases, this activation results in clonal 
proliferation and the production of effector T cells and memory T cells (Dimeloe et al., 2017).  
 
1.3.4 Innate Lymphoid Cells 
In the absence of specific antigen receptors, ILCs respond to stress signals and, through the 
production of cytokines, play a role in orchestrating the immune response. They have been 
shown to be important in early immune responses and in maintaining epithelial integrity 
(Spits et al., 2013, Hazenberg and Spits, 2014, McKenzie et al., 2014, Mjosberg and Spits, 
2016). The earliest recognised subsets of ILCs were natural killer (NK) cells and lymphoid 
tissue inducer (LTi cells), first described in mice in 1975 (Kiessling et al., 1975) and 1997 
(Mebius et al., 1997) respectively. More recently subsets that produce cytokines in a manner 
that mirrors the cytokine production profile of T helper subsets have been described. These 




Figure 1.2 Key cytokine production by subsets of ‘helper’ ILCs. The major transcription 
factors required for the development of each subset is indicated above the cell type. 
 
In healthy people, approximately 0.01%-0.1% of circulating lymphocytes are ILCs (CD127+) 
(Hazenberg and Spits, 2014). Tissue distribution is variable, but given the functions described 
above, it is not surprising that they are commonly found at the barrier surfaces. ILC2s 
predominate in the skin, where they account for approximately 3% of leucocytes, and are also 
the dominant ILC population in the lung (excluding NK cells) and the lamina propria of the 
large intestine. ILC3s predominate in the lamina propria of the small intestine (1-1.5% of 
leucocytes), but smaller populations are also found the large intestine, lung, liver and skin. 
ILC1s predominate in the intra epithelial compartment of the small and large (after NK cells) 
intestine, but small populations are widely distributed (Kim et al., 2016). It has been proposed 
that a further subset of ILCs, ‘ILCregs’, which produce IL-10, but do not express Foxp3 are 
found in the intestine of both humans and mice (Wang et al., 2017). ILCregs have also been 
identified in the nasal and respiratory tract, where numbers are increased in chronic 
inflammation. In this study, up-regulation of retinoic acid resulted in conversion of ILC2s to 

































1.3.5 ILC nomenclature 
When initially described, ILC subsets were given multiple names by different groups. In an 
attempt to unify the definitions, a proposal for their nomenclature was made in 2013 (Spits et 
al., 2013). This defined ILC groups based on the pattern of cytokine production. The proposed 
nomenclature differentiates between ‘Group X’ and ‘ILCXs’. For example Group 1 ILCs 
includes NK cells and ILC1s (all other cells that require Tbet and produce the Th1 cytokine 
IFNγ). ILC1s, unlike NK cells, have been shown not express perforin, granzyme B or IL-
15Rα (Bernink et al., 2013). Group 2 ILCs (which have been termed nuocytes, natural helper 
cells and innate helper 2 cells) require GATA binding protein 3 (GATA3) and produce Th2 
cytokines, including IL-4, IL-5 and IL-13, when stimulated. It is suggested these cells are all 
termed ILC2s. Group 3 ILCs require retinoic acid-related orphan receptor γt (RORγt) for 
development and produce IL-17 and/or IL-22. The earliest cells in this class to be described 
were LTi cells, which are required for the formation of secondary lymphoid tissue in the 
embryo.  The remaining RORγt dependent cells, ILC3s, can be divided into NCR+ ILC3s 
(expressing NKp44 in humans/NKp46 in mice) which produce IL-22, but not IL-17A and 
NCR-ILC3s, which produce IFNγ, IL-17A and IL-22.  
 
1.3.6 Development 
ILCs, like other lymphocytes derive from the common lymphoid precursor (CLP). Three 
developmental stages have been proposed using mouse models (Serafini et al., 2015). In stage 
one, the common ILC precursor (CILP) develops from the CLP. This process is dependent on 
IL-7, and the transcription factors ID2 (Inhibitor of DNA Binding 2), NFIL3 (nuclear factor 
IL-3 induced), and potentially GATA3. The three subsets of ILCs develop during stage two. 
Key transcription factors for each group have been discussed previously, with T-bet being the 
key transcription factor for ILC1s, GATA3 for ILC2s (although several other transcription 
factors including RORα have also been shown to be important) and RORγt for ILC3s. Stage 
three, maintenance of these groups, is thought likely to be the result of local regulation, with 
IL-7 again playing a key role. Whether ILCs develop in the bone marrow in adults, or 
peripherally remains unclear. Nor is it clear how numbers of ILCs increase in response to 
challenges – through recruitment and proliferation of mature cells, or through progenitors 
localising to the relevant site. It has, however, been proposed that final differentiation into 
ILC subsets may take place peripherally, dependent on cytokine signals produced by the local 
tissues (Lim and Di Santo, 2019). One example, in a mouse model, has demonstrated that 
increasing the availability of IL-7 improves survival and increases proliferation and 




There is evidence for plasticity between subtypes of ILCs. NCR+ ILC3s from foetal gut or 
tonsil, cultured with IL-2 and IL-12, will differentiate into (CD127+) ILC1s (Bernink et al., 
2013). This may be (part of) the cause of the increased CD127+ ILC1s observed in the 
intestines of patients with a flare of Crohn’s disease, which causes elevated levels of IL-12. 
CD127+ ILC1s will also differentiate towards ILC3s when cultured with IL-2, IL-1β and IL-
23, and then produce IL-22 instead of IFN-γ, a process that is enhanced by retinoic acid. 
CD103+ ILC1s (low level CD127 expression) will not become ILC3s or produce IL-22. This 
plasticity may be induced by dendritic cells (DCs) in vivo. CD127+ ILC1s adopt an ILC3 
phenotype when cultured with CD14- DCs, but maintain their original phenotype when 
cultured with CD14+ DCs. In contrast, NKp44+ ILC3s will differentiate into CD127+ ILC1s 
in the presence of CD14+ DCs, but maintain their original phenotype when cultured with 
CD14- DCs (Bernink et al., 2015). In addition, ILC2s in the lung have been shown to adopt 
and ILC1-like, IFNγ producing phenotype in the presence of IL-12 and IL-18. The relative 
reduction in frequency of ILC2s and increase in ILC1s has been shown to associate with 
disease severity in chronic obstructive airways disease (Silver et al., 2016, Bal et al., 2016). 
Plasticity has also been shown within ILC subsets. NCR- ILC3s isolated from human skin 
have been shown to differentiate to NCR+ ILC3s when cultured with IL-2, IL-23 and IL-1β 
(Teunissen et al., 2014). 
 
This plasticity between subtypes poses both difficulties and opportunities for the use of ILCs 
as cellular therapy. Potential switches between subtype, with functional implications, must be 
well understood prior to their use as treatment. 
 
1.3.8 ILCs in allogeneic stem cell transplant 
In murine models of transplantation, it has been shown that ILCs in the lamina propria survive 
transplant conditioning, and that IL-22 production by recipient ILCs plays an important role 
in protecting the recipient from GVHD (Hanash et al., 2012). A human study, however, 
showed that circulating ILCs had achieved full donor chimerism in five of six patients by 
seven weeks post-transplant (Munneke et al., 2014). This paper demonstrates that NCR+ 
ILC3s, not normally found in the peripheral blood of healthy individuals are found following 
both induction chemotherapy and HSCT. Post induction chemotherapy but pre-HSCT, 
patients could be divided into two groups based on high or low expression of the activation 
marker CD69 on ILCs, with high CD69 expression associating with the development of less 
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severe mucositis and less acute GVHD, suggesting that initial protection from tissue damage 
might reduce the development of GVHD. At 12 weeks post allograft, patients who had not 
developed, and would not go on to develop acute GVHD had the highest number of 
circulating NCR+ ILC3s. It is proposed that recipient ILCs may give tissue protection during 
conditioning treatment and so reduce the risk of developing GVHD. Although IL-22 is not 
measured in this study, given the known function of NCR+ ILC3s, and what has previously 
been shown in murine models, this represents one potential mechanism. 
 
1.3.9 Sensitivity to chemo/radiotherapy 
That IL-22 producing ILCs were radio-resistant was initially inferred from their presence 
(although in reduced numbers) three days post BMT in a mouse model investigating the role 
of IL-22 in thymic regeneration (Dudakov et al., 2012), and Hanash and colleagues 
subsequently demonstrated ILCs of recipient origin in the lamina propria of mice post BMT 
(Hanash et al., 2012).   
 
In patients with AML, numbers of circulating ILCs have been shown to fall following 
chemotherapy, with some recovery between cycles, although the authors note that this is 
incomplete in comparison to other innate cells, with differences between subsets, including an 
increase in NCR+ ILC3s. ILCs were ‘decimated’ by conditioning chemotherapy (Busulfan, 
Cyclophosphamide +/- ATG, Fludarabine, TBI +/- ATG or Fludarabine, Busulfan +/- ATG). 
This apparent greater resistance to radiotherapy than chemotherapy is important when 
considering the role of ILCs in murine models of BMT compared to human HSCT, as 
conditioning in mice is often performed with TBI alone, while this is not standard practice in 
humans.   
 
1.3.10 Autoimmunity 
Autoimmunity occurs when mechanisms for self-tolerance have failed. During T cell 
development, T cells that bind with too great an affinity to the MHC/self peptide complex 
should be negatively selected and undergo cell death. Why this process sometimes fails is 
poorly understood, but when these self-reactive T cells are not deleted, they may cause 
autoimmune diseases (Sakaguchi, 2000, Jessop et al., 2019). 
Although GVHD results from allo-reactive, rather than auto-reactive T cells, the clinical 
manifestations are often similar. For this reason, many of the models discussed in this thesis, 
especially in relation to IL-22, draw on models from the field of autoimmunity. 
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Finally, transplantation (usually autologous) can itself be used in the treatment of severe 
autoimmune conditions, most commonly multiple sclerosis, systemic sclerosis, and Crohn’s 
disease. The aim is to initially immunosuppress the patient to reduce inflammation, with the 
hope of then ‘resetting’ the immune system. Responses are variable, but can be of significant 




IL-22, coded for in humans on chromosome 12 (12q15), is part of the IL-10 cytokine family. 
It has been shown to have both pro-inflammatory and regulatory effects, depending on the 
situation in which it is produced (Dudakov et al., 2015). 
 
1.4.1 The IL-22/IL-22R system 
IL-22 is produced by a number of leucocytes, including Th17 and Th22 cells, γδ T cells, NK 
cells mucosal-associated invariant T (MAIT) cells, and a subset of ILCs (Sabat et al., 2014, 
Lamarthee et al., 2016b, Toussirot et al., 2018). The IL-22 receptor is a heterodimer 
composed of the IL-10 receptor subunit IL-10R2 and the IL-22 specific IL-22R1 (Dudakov et 
al., 2015, Sabat et al., 2014). While IL-10R2 is relatively widely distributed, IL-22R1 is not 
expressed on leucocytes, but is constitutively expressed on non-haematopoietic cells of the 
skin (keratinocytes), liver and intestine, the key target organs of aGVHD, in addition to the 
pancreas, kidney and lung (Wolk et al., 2004, Boniface et al., 2005). 
 
1.4.2 IL-22BP 
In addition, and homologous to extracellular IL-22R1, there is a soluble receptor for IL-22, 
known as IL-22 binding protein (IL-22BP). IL-22BP has an inhibitory effect, as it prevents 
binding of IL-22 to the trans-membrane receptor. It is constitutively expressed in the lymph 
nodes and intestine, where DCs have been shown to be an important cellular source (Sabat et 
al., 2014, Lamarthee et al., 2016b, Wolk et al., 2007, Martin et al., 2014). In a dextran 
sulphate sodium (DSS) model of colitis, an inverse relationship between IL-22 and IL-22BP 
was shown, where at the time of peak disease, Il22 expression had increased and Il22bp had 
fallen, with both subsequently returning towards baseline. This study also identified DCs as 
having high levels of IL-22BP expression (Huber et al., 2012). Interestingly, in a study of 
humans with inflammatory bowel disease, IL-22BP was found to be increased, thus reducing 
the protective function of IL-22. In addition, eosinophils were shown to be an important 
source of IL-22BP in this setting (Martin et al., 2016). This final study is of particular interest, 
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as the presence of eosinophilia is commonly seen in GVHD (Daneshpouy et al., 2002, Basara 
et al., 2002). 
 
1.4.3 Downstream effects of IL-22 binding 
Binding of IL-22 to the trans-membrane receptor activates Janus kinase 1 (JAK1) and 
tyrosine kinase 2 (Tyk2), and so phosphorylates signal transducer and activator of 
transcription (STAT) 3 and to a lesser extent STAT1 and STAT5. A simplified representation 
of this axis is shown in Figure 1.3. The functions of IL-22 include the production of anti-
microbial peptides, tissue repair and the induction of epithelial cells to increase the production 
of mucous associated molecules, thus increasing the mucous barrier and reducing gut 
translocation. In the skin, IL-22 also reduces the terminal differentiation of keratinocytes 





Figure 1.3 A simplified representation of the IL-22-IL-22RA axis, adapted from Sabat et al 









































                
1.4.4 Pro-inflammatory role 
One of the models to best demonstrate the link between IL-22, ILCs and inflammation is 
psoriasis. Elevated levels of IL-22 expression in the skin of psoriasis and atopic dermatitis 
patients compared to healthy controls were demonstrated by Wolk and colleagues in 2004 
(Wolk et al., 2004). The number of NKp44+ ILC3s has been shown to be increased in both 
the blood and skin of patients with psoriasis. In addition, a single case in this study was 
followed after treatment with an anti-TNF monoclonal antibody. A reduction in the number of 
NKp44+ ILCs correlated with a reduction in the Psoriasis Area Severity Index (PASI) 
(Villanova et al., 2014). This work was taken one step further in vitro by Teunissen and 
colleagues (Teunissen et al., 2014), who demonstrate not only an increase in the number of 
NCR+ ILC3s in the skin and blood of patients with psoriasis, but also that NCR- ILC3s will 
become NCR+ under the influence of IL-1β and IL-23 (both known to play a role in psoriasis) 
and that the NCR+ cells are IL-22 producing. Psoriasis is interesting as an example of the 
pathogenic role of IL-22, because the lesions are the result of over activity of the normal 
proliferative function of IL-22. 
 
1.4.5 Regulatory role 
The role of IL-22 in inflammatory bowel disease (IBD) has been studied in a number of 
mouse models. In DSS induced colitis, the administration of an IL-22 neutralizing antibody 
resulted in increased colonic inflammation and greater destruction of the epithelium. In a T 
cell transfer model, T cells from an IL-22-/- mouse caused more severe colitis than wild type T 
cells. In addition, it has been shown that the administration of recombinant IL-22 (rIL-22) 
resulted in recovery of intestinal inflammation (Li et al., 2014). These results suggest a 
protective role for IL-22 in IBD. It has been proposed, however, in a DSS model of colitis 
associated colon cancer, using an anti-IL-22 antibody that although IL-22 does have a 
protective effect in the acute period, it has a negative impact in the recovery period (Huber et 
al., 2012). 
 
Similarly, a protective role for IL-22 has been shown in a murine model of hepatitis. 
Concanavalin-A (Con A) was given to induce a transaminitis with associated necrosis. 
Hepatic damage was more severe when mice were given an IL-22 neutralising antibody and 
ameliorated when they were pre-treated with rIL-22 (Radaeva et al., 2004). The same effect 
was seen with rIL-22 in alcohol induced liver injury in mice (Ki et al., 2010). When STAT3 
was deleted in the hepatocytes, this protective effect from IL-22 was lost. 
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1.4.6 IL-22 in allogeneic stem cell transplant 
The role of IL-22 in HSCT remains unclear. A murine model has demonstrated the protective 
role of IL-22 for the transplant recipient. Initially an IL-22 neutralising antibody was used in 
an MHC mismatched transplant model, resulting in a significant increase in GVHD related 
mortality. Subsequently, using an IL-22 knockout MHC mismatched model, it was 
demonstrated the knockout mouse could be used as the donor with no effect on GVHD 
incidence (and a delay in GVHD mortality, with combined donor marrow and T cell IL-22 
deficiency). When the IL-22-/- mouse was the transplant recipient, however, there was a 
significant increase in GVHD mortality. The effect was particularly prominent in the 
gastrointestinal tract, where (radio-resistant) ILC-produced IL-22 was key in reducing 
damage to intestinal stem cells, resulting in reduced morbidity and mortality from gut GVHD. 
GVHD itself, however, resulted in a reduction of ILC numbers, and of IL-22. Interestingly, no 
difference was seen in skin pathology in Il22-/- recipients. It is important to subsequent 
discussion to note that levels of IL-22 in the gastrointestinal tract rose in response to 
conditioning (Hanash et al., 2012). 
 
It was subsequently demonstrated that administration of recombinant IL-22 (starting at Day 7 
post HSCT), again in a murine model, resulted in reduced GVHD pathology in the gut and 
liver (but not skin) at three weeks post-transplant (Mertelsmann et al., 2013).  
In contrast to this, two papers looking at the role of donor produced IL-22 in murine GVHD 
demonstrate in a MiHA model that mice receiving T cells from IL-22 knockout donors have 
reduced GVHD related mortality and a reduced histological grade of GVHD in the skin and 








We propose that, as in the mouse model (Hanash et al., 2012), ILC3 derived IL-22 protects 
target organs from GVHD by protecting the recipient’s tissues from conditioning induced 
damage, resulting in reduced T cell activation. The role of IL-22 in established GVHD may, 
however, be pro-inflammatory, and if so, the point of change is not well established. The aim 
of this project is to further clarify the role of ILCs and IL-22 in a human transplant setting, 
and so to develop a clearer understanding of their potential therapeutic use.  
 
Overall aims of the project: 
 
Aim 1: to define innate lymphoid cell homeostasis in human haematopoietic stem cell 
transplantation 
 
Aim 2: to analyse the IL-22 axis in human graft versus host disease 
 










2.1.1 ILC function to maintain health  
Primarily resident at epithelial surfaces, ILCs have a variety of functions to maintain health. 
They have been shown to have a role containing natural commensal bacteria within the gut 
(Sonnenberg et al., 2012). In a Rag1-/- mouse model, the group demonstrate that depletion of 
ILCs resulted in dissemination of commensal bacteria, with resulting systemic inflammation. 
Of particular interest to this project, signs of systemic inflammation were also produced if 
Rag1-/- mice (without ILC depletion) were treated with an IL-22 blocking antibody. 
Anatomical containment and reduction in inflammation could be restored by the 
administration of recombinant IL-22. 
 
Further evidence of the importance of ILC-produced IL-22 in the gut was shown in a reporter 
mouse model (Sawa et al., 2011). The authors show that ILCs (both NCR+ and LTi), are the 
major producers of intestinal IL-22 and that unlike T cells, they do so constitutively. 
Furthermore, there was evidence of direct feedback between the microbiota and ILCs. 
Expression of IL-25 by epithelial cells, induced by the microbiota, reduced IL-22 production. 
The authors propose this is a mechanism by which equilibrium is maintained between the 
microbiota and the immune system. In addition, ILC3s (and to a lesser extent ILC2s) have 
been shown to express MHC II (Hepworth et al., 2013). In a mouse model, depletion of ILCs 
using an anti-CD90.2+ monoclonal antibody resulted in increased, dysregulated CD4+ T 
cells, not seen in IL-22, IL-17A, and IL-23 deficient mice, suggesting an alternative 
mechanism. When MHC II was deleted from ILCs alone, mice developed intestinal 
inflammation, with loss of normal architecture and increased numbers of IFN-γ, IL-17 and 
TNF-α producing CD4+ cells in the colon compared to controls. This inflammation was 
prevented if the mice were treated continuously with antibiotics.  The authors propose that 
antigen presentation by ILCs, without the necessary co-stimulation, negatively regulates 
CD4+ T cells. In a subsequent publication (Hepworth et al., 2015), MHC II+ CCR6+ ILC3s 
were found to induce apoptotic cell death and deletion of activated commensal specific T 
cells, so maintaining intestinal homeostasis. The authors comment that this process is similar 
to negative selection in the thymus, and propose the use of the term ‘intestinal selection’. Of 
interest to the subsequent discussion of IL-7, one of the hypotheses tested in vitro was that the 
high levels of the IL-2R and IL-7R expressed by the ILCs may mean that the cell death 
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induced is a combination of the apoptotic pathway, with reduction in availability of pro-
survival cytokines. They were, however, able to reduce cell death with the addition of 
recombinant IL-2 but not IL-7.  
 
A single report in humans undergoing HSCT for severe combined immunodeficiency (SCID) 
with IL-2 receptor (IL2R) or Janus kinase-3 (JAK3) mutations has questioned whether ILCs 
are redundant in humans with a functional adaptive immune system (Vely et al., 2016). These 
patients lack ILCs in addition to T cells. With low intensity conditioning, the protocols 
resulted in T cells of donor origin, while other lineages remained of host origin. They 
therefore continued to lack ILCs in the post-transplant setting. In follow-up extending to a 
maximum of 39 years, these patients did not see an increase in infection or inflammation 
when compared to patients transplanted for comparable immunodeficiencies. It should be 
noted that the majority of this work was performed on peripheral blood. 
 
2.1.2 ILC involvement in pathology 
ILCs have been shown to be pathological in a number of situations. An increased frequency 
of IL-22 producing ILC3s has been shown in the skin and blood of patients with psoriasis 
(Teunissen et al., 2014, Villanova et al., 2014). Interestingly, the number of ILC3s was found 
to correlate with the severity of the disease (as determined by the psoriasis area severity index 
– PASI), and a reduction in circulating ILC3s was closely associated with a clinical response 
to an anti-TNF agent. 
 
Disordered composition of ILCs has been demonstrated in the intestines of patients with 
Crohn’s disease compared to controls (with colorectal cancer) (Bernink et al., 2013). Patients 
with Crohn’s disease had a higher percentage of ILC1s and lower percentage of Nkp44+ 
ILC3s. These ILC1s were shown to express IFNG, known to be increased in the lamina 
propria in patients with Crohn’s disease. Plasticity between these ILC subsets has been 
discussed previously (1.3.3). Total ILC percentage of leucocytes was not significantly 
different. 
 
2.1.3 IL-7 and its role in SCT 
First described in a culture system in 1988, where it was shown to stimulate lymphoid 
progenitors (Namen et al., 1988), IL-7 is member of the common γ chain family (IL-2, IL-4, 
IL-7, IL-9, IL-15 and IL-21)(Lin and Leonard, 2017), its receptor being comprised of the IL-
7α subunit (CD127) and the IL-2Rγ chain (CD132, the common γ chain receptor). Mutations 
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in the IL-2Rγ chain result clinically in X-linked SCID (Leonard, 1996). IL-7 is known to be 
critical for lymphocyte development, with IL-7-/- mice showing similar abnormalities of 
lymphocytes to mice lacking the IL-2Rγ (von Freeden-Jeffry et al., 1995, DiSanto et al., 
1995).  
 
In 2001 it was proposed that IL-7 might be involved in T cell homeostasis (Fry et al., 2001). 
They demonstrated an inverse correlation between IL-7 and CD4 count in two cohorts, 
paediatric patients with HIV infection and patients undergoing chemotherapy. In both groups 
there was an increase in IL-7 concentration when the CD4 count was low, and a fall following 
CD4 recovery. In the paediatric patients, some correlation was also seen between IL-7 and 
CD8 cells, but this was absent in the post chemotherapy cohort. No correlation was found 
with the other cytokines tested. Based on these findings, the authors propose two possible 
mechanisms of IL-7 homeostasis. IL-7 may be produced at a constant rate, but when T cell 
numbers fall, the reduction in IL-7R results in increased IL-7 availability, or a reduction in T 
cells results in increased IL-7 production. Further evidence linking IL-7 concentration with 
lymphocyte homeostasis is seen in a study looking at serum IL-7 levels peri-HSCT in a 
paediatric setting. Patients were undergoing transplantation for SCID, thalassaemia, aplastic 
anaemia or acute leukaemia. The pre-HSCT IL-7 concentration was inversely correlated with 
the absolute lymphocyte count, and during transplant, in the acute leukaemia and SCID 
patients the IL-7 concentration rises as the lymphocyte count falls, and then falls as the 
lymphocyte count recovers (Bolotin et al., 1999). The authors argue in favour of a reduction 
in IL-7 binding in the lymphopenic setting. Fry et al., however, have a third population in 
their study, patients with idiopathic CD4 lymphopoenia. In this cohort, no correlation is seen 
between CD4 count and serum IL-7 levels. The authors argue that this makes the first model 
less likely. 
 
2.1.4 IL-7 as therapy post HSCT 
Given the known function of IL-7, it is perhaps not surprising that groups have attempted to 
improve immune reconstitution post HSCT using recombinant IL-7. In 2002, Sinha et al. 
(Sinha et al., 2002) demonstrated improved thymopoiesis in a syngeneic and T cell depleted 
mouse model, when IL-7 was administered daily for 28 days, commencing on the day of stem 
cell return. In this T replete setting, however, IL-7 administration resulted in the development 
of clinical GVHD at a lower T cell dose, and increased histological changes in GVHD target 
organs. In these animals there was no improvement in thymic function, presumed to be due to 
the toxic effect of GVHD on the thymus.  
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Endogenous IL-7 has also been linked to GVHD. In a study of 31 patients, receiving identical 
conditioning with fludarabine and cyclophosphamide, higher serum IL-7 concentration at Day 
7 and Day 14 were associated with subsequent aGVHD development (Dean et al., 2008).  
 
2.1.5 ILCs and the role of IL-7  
As previously discussed, IL-7 plays a critical role in T cell reconstitution post HSCT, 
however, the mechanism that governs IL-7 homeostasis has remained somewhat elusive. In 
2017, (Martin et al., 2017) a series of murine models were used to investigate IL-7 
homeostasis.  Initially using bone marrow chimeric mice that only expressed IL-7 in stromal 
or haematopoietic cells, it was determined that stromal cells are key to IL-7 production in this 
model, with only a small proportion of IL-7 being haematopoietic cell derived. This concept 
was then developed, through the production of chimeras where IL-7R was expressed in either 
haematopoietic or stromal cells. Here the relative cellular importance was reversed, with 
donor T cell proliferation being affected by the expression of the IL-7R on haematopoietic but 
not stromal cells. Using observations from the literature that IL-7 concentration in Rag-
deficient mice is not as high as that seen in Il7r-/- mice, they hypothesise that cells other than 
T cells must be using the available IL-7. Using a CD90.2 antibody to deplete ILCs in Rag1-/- 
recipients, increased T cell proliferation was demonstrated when compared to Il7-/- recipients 
treated with the same antibody. It was further demonstrated that ILCs (defined as CD90+ 
NK1.1- cells) were more efficient than T cells at utilising IL-7, and did not down-regulate IL-
7R to the same extent as T cells when cultured with IL-7. Furthermore, when donor T cells 
were transplanted into mice that had undergone ILC depletion, they showed increased 
proliferation. This effect was lost in Il7-/- hosts. 
 
Evidence for reduced T cell proliferation in the presence of increased IL-7 competition had 
been shown in an earlier paper (Munitic et al., 2004). Here, a transgenic mouse was produced, 
where the T cells expressed IL-7R throughout their lifetime (CD4+ CD8+ thymocytes do not 
usually have detectable levels of IL-7R). The transgenic mice showed evidence of thymic 
hypoplasia, with increased apoptosis of CD4- CD8- cells, and an overall reduction in their 
number. The authors propose that the increased competition for IL-7 in effect “starves” the 





2.1.6 ILCs and CD52 expression 
When this research began, to my knowledge, no published data were available regarding the 
expression of CD52 by ILCs. Increasing interest in the use of Alemtuzumab for the treatment 
of multiple sclerosis, combined with an interest in the role of ILCs in the disease, means that 
there are now published data showing CD52 expression by ILCs (Gross et al., 2016). The 
paper explores the effect of treatment with Alemtuzumab on circulating innate immune cells. 
CD52 expression is seen on ILCs, although at a lower level than on CD4+ T cells (in 
treatment naïve patients with multiple sclerosis).  
 
2.1.7 Graft sources in allogeneic SCT 
Current in vitro manipulation (such as CD34 selection or αβ T cell depletion) has increased 
the number of potential graft types given to the recipient, but stem cells are still harvested 
from three sources: bone marrow, mobilised peripheral blood stem cells or cord blood. 
Different graft sources are known to have different compositions of T cells, monocytes and 
NK cells (Korbling and Anderlini, 2001, Servais et al., 2017). These known differences do 
not, however, consistently translate into a difference in aGVHD risk (Ringden et al., 2002, 
Hahn et al., 2008, Lazaryan et al., 2016), although it is often difficult to separate the effect of 




2.1.8 Questions for Chapter 2 
Chapter 2 explores ILC homeostasis in human HSCT. The specific questions addressed are 
detailed below. 
 
1. What is the effect of transplant conditioning therapy, including T cell depletion, on ILCs? 
 
2. What is the effect of lymphopenia on the expansion of ILCs post-transplant? 
 
3. What is the response of IL-7 to conditioning regimens and subsequent lymphopenia? 
 
4. Does ILC reconstitution impact on the development of GVHD? 
 




1. To use flow cytometry to assess ILC homeostasis in human HSCT 
Is this affected by T cell depletion? 
Is there an association with GVHD? 
 
 
2. To use ELISA to explore IL-7 homeostasis during HSCT 
 
 
3. To evaluate the ILC content of different stem cell sources  
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2.2 Methods for Chapter Two 
2.2.1 Sample collection 
All samples used in this chapter were collected under the ‘Improving Outcomes in HSCT’ 
project. Ethical approval was granted by the NRES Committee North East – Newcastle & 
North Tyneside 2 (14/NE/1136). This non-interventional study was designed to meet a 
number of objectives in adult HSCT, including improving our understanding of the cellular 
immune reaction in GVHD and developing new strategies for GVHD prediction. Patient 
blood samples (both EDTA and serum) were taken with routine clinical samples. Both 
patients and healthy controls gave informed consent. 
 
The majority of work using patient samples in this thesis was performed on two cohorts of 
patients who underwent HSCT at the Northern Centre for Bone Marrow Transplantation 
between 2015 and 2019 (Cohort A and Cohort B), the full details of which are shown in 
Appendix 1. Where specific subsets of these patients, or additional samples have been used, 
relevant clinical information is provided with the results. Patients in Cohort A were recruited 
sequentially by date of transplant, but once six patients were recruited to each T cell depletion 
group, that group closed. Patients in Cohort B were recruited sequentially. 
 
Samples from graft sources: Bone marrow and peripheral blood stem cell (PBSC) samples 
were performed on fresh samples, using excess material from clinical harvests. Cord blood 
samples had been previously frozen, and were defrosted as below. It is worth noting, that this 
mirrors the clinical use of these graft sources, where both bone marrow and mobilised PBSCs 
are routinely donated and infused fresh, while cord blood will have been frozen and defrosted 
prior to infusion. 
 
2.2.2 Media and buffers 
Details of media and buffers used in this chapter are provided in Appendix 2. 
 
2.2.3 Clinical data 
Clinical data were taken from the BMT Clinical Database, laboratory systems, and where data 
were missing, from patient notes.  
 
2.2.4 Cell processing - PBMCs 
Peripheral blood mononuclear cells (PBMCs) were extracted from fresh blood (taken in 
EDTA) using the following method. Blood was diluted 1:1 with D-PBS and then layered on 
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15mls LymphoprepTM density-gradient media (Alere Technologies). The sample was then 
centrifuged at room temperature (800g for 15 mins). PBMCs were aspirated, washed in D-
PBS (centrifuged at 500g for 5mins) and then underwent a further wash to remove platelets 
(300g for 7 minutes). The pellet was re-suspended in 1ml of red blood cell lysis buffer 
(Sigma-Aldrich) and incubated in the dark for 10 minutes. The cells were washed again in D-
PBS. Total cell count was estimated using a 1:1 dilution with trypan blue exclusion dye 
(InvitrogenTM, Thermo Fisher Scientific) on an Improved Neubauer Haemocytometer (Weber 
Scientific International).  
 
Cells from mobilised PBSCs and bone marrow were collected fresh at the time of donation 
and washed. Cryopreserved cord blood samples were defrosted into warm RF10, and washed 
twice. All cells were counted as above, and re-suspended in 50µl flow buffer. 
 
2.2.5 Cell preparation 
4µl anti-mouse IgG (Sigma-Aldrich) was added to the sample and incubated for 4 minutes. 
Antibodies were then added as per the panel and incubated at 4oC in the dark for 30 minutes. 
The cells were washed in flow buffer (500g for 5 minutes) and re-suspended in 200µl flow 
buffer.  4,6-diamidino-2-phenylindole (DAPI; Partec) was used to exclude dead cells. 
 
2.2.6 Trucounts – cell processing 
Peripheral blood samples, collected in EDTA, were inverted a minimum of 20 times to ensure 
thorough mixing. 200µl of whole blood was mixed with the Trucount antibody panel (details 
in Appendix 3) in a TrucountTM tube (BD Biosciences), and stained for 20 minutes in the dark 
at room temperature. The sample was then lysed with 900ul of RBC lysis buffer. 
 
2.2.7 Gating strategy (Trucounts) 
In this panel, I was interested in accurate CD3 and total ILC counts. In order to include the 
additional markers, this panel does not enable sub-setting of ILCs. An example of the 
Trucount gating strategy is shown in Figure 2.1. Details of the panel and antibodies used are 





Figure 2.1 An example of the gating strategy used for the Trucount samples. 200µl of whole 
blood was mixed with the Trucount antibody panel (CD3, CD4, CD8, CD14, CD16, CD19, 
CD20, CD34, CD45, CD56, CD127, HLA-DR) 
 
 
2.2.8 Flow cytometry 
Flow cytometry was performed using a BD LSRFortessaTM X-20. Data were analysed using 
FlowJo versions 10.1 and 10.5.3.  
 
2.2.9 Cell sorting 
Cell sorting was performed using a BD FACSARIATM Fusion. The sorted populations (CD3+ 
and ILCs) were sent to the Northern Molecular Genetics Service for chimerism analysis, as 
informative markers for each patient had already been determined for clinical use. 
 
2.2.10 Serum samples 
Serum samples were centrifuged at 500g for 5 minutes. Serum was stored in aliquots of 1ml 
at -800C.  
 
2.2.11 Serum IL-7 quantification 
IL-7 quantification was performed using a human IL-7 Quantikine HS enzyme-linked 
immunosorbent assay (ELISA) Kit (R&D systems). The assay was performed according to 
the manufacturers instructions. Briefly, a dilution series was produced using the human IL-7 
standard provided, to produce standards, which were tested in duplicate. 200µl of standard or 
sample was placed in each well of a 96 well plate and incubated for 14-20 hours. Based on the 
results of a preliminary experiment, samples were diluted 1:10 with calibrator diluent, to 
ensure results were within the range of the standard curve. Samples were tested in singlet. 
Each well was washed six times with wash buffer and 200µl of human IL-7 conjugate was 
added to each well. The plate was then incubated for a further two hours at room temperature. 
Each well was then washed a further six times, after which 50µl of substrate solution was 
added per well. The plate was incubated for a further 45 minutes at room temperature, after 
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minutes, after which 50µl of stop solution was added to each well. The optical density was 
measured using a Multiskan Ascent®plate reader (Multiskan Ascent, Thermo Labsystems, 
Thermo Fisher Scientific), set at 690nm and 492nm, and data were analysed using Ascent® 
software. 
 
To calculate the values, the readings at 690nm were subtracted from those at 492nm. All 
values were log-transformed and non-linear regression was performed using GraphPad Prism 
(version 7). Final values were multiplied by ten, to account for the initial dilution. The 
minimum detectable value of the assay was 0.1pg/mL.  
 
Serum IL-22 quantification was performed using a human IL-22 Quantikine enzyme-linked 
immunosorbent assay (ELISA) Kit (R&D systems). The assay was performed according to 




2.3  Results 
2.3.1 CD52 expression by ILCs 
As discussed, at the time of starting this project, published data were not available for CD52 
expression by ILCs. As Alemtuzumab is given in approximately 60% of the adult allogeneic 
stem cell transplants performed at the Northern Centre for Bone Marrow Transplantation, 
prior to looking at ILC homeostasis in stem cell transplantation, I first wished to establish 
whether ILCs expressed CD52. Figure 2.2 shows the results from experiments using four 
healthy donors. Part a) shows the standard gating strategy, discussed further in 2.3.3, for 
CD52 versus (top) an isotype control (below). Part b) demonstrates that CD52 expression was 
seen on the combined ILC population of all four donors, when compared to an isotype control 





Figure 2.2 a) CD52 expression on combined ILC population (top) vs isotype control (below), 
b) CD52 expression demonstrated on whole ILC population (four healthy controls compared 
to an isotype control in grey), c) CD52 expression demonstrated on all ILC subsets (ILC1 



































2.3.2 Patient Characteristics 
In order to investigate ILC homeostasis, peripheral blood samples were collected from 
patients undergoing HSCT. Samples were collected from two separate cohorts. In Cohort A, 
patients were recruited into four groups, with six patients in each, based on the T cell 
depleting agent he or she received (or none). Four standard regimens are used in our 
institution: T cell replete, ATG, 30mg Alemtuzumab or 60mg Alemtuzumab. One additional 
patient was recruited into the 60mg Alemtuzumab group, due to one early death in that group. 
Samples for this group were collected at the following time points: 
 
Admission Day 0 Day 7 Day 14 Day 21 Day 28 Day 56 Day 100 
 
10mls of peripheral blood was requested at each time point, and a total of 156 samples were 
received. PBMCs were isolated from these samples and analysed using panel ILCA. A 
summary of the patient characteristics is shown below and more detailed information is 
shown in Appendix 1 (Cohort A). As the choice of T cell depletion is dependent on 
conditioning regimen, disease and donor, there are obvious mismatches between the groups. 
Our standard practice is to use the Seattle protocol for patients with myeloma, ATG as part of 
a FLAMSA protocol, 30mg Alemtuzumab with the majority of sibling donors and 60mg for 
matched unrelated donors. The first adult transplant using a haploidentical donor in our 
institution was performed in 2015.  
 
For validation purposes, and to allow for the collection of additional serum samples, a second 
cohort of transplant patients was collected. Due to time constraints, Cohort B consists of 
sequential patients who gave consent to be part of the study. Blood was analysed using the 
Trucount method, using the panel shown in Figure 2.1. Samples were collected at Day 14, 
Day 28, Day 56 and Day 100, with a total of 73 samples received.  
 
The two cohorts were subsequently combined for analysis (2.3.5). A summary of patient 
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Table 2.1 Patient characteristics for Cohorts A & B, split by method of T cell depletion 
 
2.3.3 Panels ILCA and ILCB 
Both panel ILCA and ILCB were run using isolated PBMCs. An initial panel to allow ILC 
isolation and subtyping (ILCA) was designed using a combination of isotype controls and 
fluorescence minus one panels (examples are shown in Appendix 4). Relevant antigen 
expression was taken from the literature, drawing especially on the following publications: 
Munneke et al (Munneke et al., 2014), Hazenberg and Spits (Hazenberg and Spits, 2014), 
Teunissen et al (Teunissen et al., 2014). 
The gating strategy involved isolation of live single cells. Lymphocytes were then gated using 
CD45 expression, and from this gate ILCs were isolated as lineage negative, CD127+, where 
the lineage gate included CD3, CD14, CD16, CD19, CD20, CD34, CD123. Subdivision into 
ILC1, ILC2 and ILC3 was then possible using CD117 and CRTH2. An example of the gating 
strategy is shown in Figure 2.3. Cell sorting was performed using panel ILCB. The gating 
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strategy was similar, but an additional gate was added to allow sorting of CD3+ cells 
separately. An example of the panel used for cell sorting is shown in Figure 2.4. A list of 
panels and antibodies used in is shown in Appendix 3. 
 
One of the difficulties of assessing ILCs using flow cytometry, is that they are primarily 
defined by the absence, rather than expression of key markers. As our knowledge of ILCs 
increases, so expression of new markers is demonstrated in certain situations. For example the 
dendritic cell marker CD11c is commonly included in the lineage gate to exclude these cells, 
but CD11c expression has been demonstrated on IL-22 producing NKp46+ cells in a mouse 
model of C. rodentium-induced colitis (Satoh-Takayama et al., 2008). Given the 
inflammatory state post HSCT, I have chosen to limit the markers included in my lineage 
gate. This reduces the likelihood of losing the cells I am interested in, but increases the 
potential for contamination within the gates. For this reason secondary analysis was 
performed using t-distributed stochastic neighbour embedding (t-SNE), to investigate whether 
the cells of interest formed a cluster, without manual gating (Figure 2.5b). 
 
 
Figure 2.3 Example of gating strategy ILCA. Live single cells were gated using CD45 to 
isolate the lymphocyte population. ILCs were then gated as Lineage negative (Lineage 
markers CD3, CD14, CD16, CD19, CD20, CD34, CD123), CD127+. Subdivision into ILC1, 




Figure 2.4 The cell sorting strategy (ILCB) altered from ILCA after the lymphocyte gate, in 




























































2.3.4 Back gating 
By double staining the cells for the key populations, I was able to demonstrate where key 
populations were located within my gates. T cells and B cells showed the highest expression 
of lineage markers, and were split primarily by CD127 expression, with T cells (light blue) 
being positive and B cells (dark green) negative. CD14 positive cells (dark blue) were a 
relatively homogeneous population with intermediate expression of lineage markers. 




Figure 2.5a Back-gating of panel ILCA to demonstrate where the major populations are 
located. The CD3+ population is shown in light blue, the CD19+ population in dark green, 




































Figure 2.5b The same data illustrated by t-SNE. ILCs form a single cluster (top panel), which 
is Lin-, CD127+. 
 
 
2.3.5 Combining Cohort A and Cohort B 
To maximise the number of patients available for analysis and therefore improve the 
statistical power of the study, it was decided to combine the two cohorts if possible. Given the 
different techniques used, it was first necessary to assess correlation between the results 
obtained. In Cohort A, flow cytometry was performed on isolated peripheral blood 
mononuclear cells. Absolute counts are therefore derived, using the cell number in the 
lymphocyte gate and the lymphocyte count from testing performed in the NHS laboratory on 
the same day. In Cohort B, analysis was performed using the Trucount method, so it was not 
necessary to subsequently derive absolute counts. To assess the degree of correlation, CD3 
and ILC counts for Cohort B were derived, using the relative proportions of the lymphocyte 
gate and the NHS laboratory count, in the same way as they had been calculated in Cohort A. 
These results were then compared to the ‘absolute’ count given by the Trucount method. The 









































Figure 2.6 Graphs showing the correlation between the two methods of calculating absolute 
cell count. The Spearman rank correlation coefficient in part (a) is 0.95, and in part (b) is 
0.97. 
 
Given the degree of correlation, it was decided to combine the results of the two cohorts for 
subsequent analysis, and to use the laboratory derived method for all samples. As the values 
from the Trucount method were consistently slightly higher, I considered adjusting the 
derived results using the gradient of the line. Given, however, that I was only able to calculate 
the gradient for Cohort B, I felt to do so was potentially introducing a further source of error. 










































It is, however, possible, that all the results shown below are slightly lower than the true 
values. 
 
I had initially intended to investigate individual subsets of ILCs. My results from Cohort A, 
however, showed so few ILCs, especially at the early time points in which I was most 
interested, that accurate subsetting was not possible. Cohort B did not contain the antigens to 
allow subsetting. The results below are therefore for total ILCs.  
 
2.3.6 ILC homeostasis in HSCT 
Looking initially at all the patients combined, both ILCs and CD3+ cells show a similar 
pattern, with a nadir reached at Day 0 (Figure 2.7). Early recovery is seen by Day 14, but for 
both cell types this is more marked by Day 28. Neither has reached the levels seen at 
admission by 100 days post-transplant. Significant intra-sample variability is seen, which is 
probably due to a number of factors, including method of T cell depletion (discussed further 
below), underlying disease and treatment received prior to transplantation, complications 
suffered post transplantation, and treatment received for these, including GVHD and viral 






Figure 2.7 Graphs showing ILC and CD3 homeostasis from admission to 100 days post-
transplant, with a nadir reached at D0 (mean with standard deviation). Neither cell type has 
































































Figure 2.8 t-SNE plots of ILC reconstitution during the first 100 days. a) The top panel 
illustrates that the Lin- CD127+ cells form a cluster. b) The four columns show that this 
remains the case at the four time points (no ILCs at Day 0). Data shown represents one 
healthy control and one reconstituting patient at each time-point shown. At each time point 
illustrated, the ILC ‘cluster’ is located in the Lin- CD127+ quadrant, consistent with the 

































































In order to confirm the identity of the small number of cells falling in the lineage- versus 
CD127+ gate, I performed a tSNE analysis of a healthy control sample concatenated with 
post-transplant samples. I identified the cluster corresponding to ILC in the tSNE map and 
confirmed that the cells in the lin- CD127 region, identified by conventional gating in the 
post-transplant samples, clustered together in the ILC region of the tSNE plot. This lends 
support to their identity as it takes into account all of the parameters in the experiment. A 
healthy control was combined with a Day 0, Day 28 and Day 100 sample (events were 
downsampled in proportion to the lymphocyte count of the sample and concatenated). Figure 
2.8 shows the samples combined in the top row, and lymphocyte reconstitution over time in 
part (b). Clustering of the Lin- CD127+ gate is shown in the penultimate row, and the final 
row shows that this cluster falls in the appropriate Lin- CD127+ zone. This provides 
additional evidence that the appropriate cells fall in my ILC gates by standard flow cytometry 
methods. 
 
2.3.7 ILC reconstitution and the impact of Alemtuzumab 
Patients were subsequently divided into two groups, those who did and those who did not 
receive Alemtuzumab as part of their conditioning therapy (Figure 2.9). Given that I had 
previously demonstrated the presence of CD52 expression on ILCs, it was interesting to 
observe the more rapid ILC recovery in those patients who did not receive Alemtuzumab. 
This difference was significant at Day 28 and Day 56 post-transplant. Not surprisingly, this 
difference was also observed in the T cell population, where the difference was statistically 
significant at all time points from Day 14 onwards. 
 
 
Figure 2.9 Graphs showing ILC and T cell recovery for all 45 patients according to use of 
Alemtuzumab. Statistically significant differences were seen for ILCs at Day 28 (p=0.04) and 
Day 56 (p=0.0001). For CD3+ cells, statistically significant differences were seen at Day 14 




































































* * * *
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ILCs are predominantly found at mucosal surfaces, so circulating ILCs may not be 
representative of total ILC numbers. It is, therefore, not possible to know whether these 
findings reflect the response of the total pool of ILCs to Alemtuzumab, or simply those found 
in the peripheral blood. The early kinetics are, however, interesting, suggesting that where the 
regimen does not include Alemtuzumab, some ILCs may survive conditioning therapy. Given 
this possibility, it was important to assess the percentage donor/recipient chimerism. 
 
2.3.8 Chimerism 
As previously discussed, there is an apparent mismatch between humans and murine models 
in relation to time to reach full donor chimerism, although tissue sources have varied. Day 28 
chimerism was successfully analysed on three patient samples, with two fractions being 
sorted for each patient, a CD3+ subset and an ILC subset (Figure 2.10). In patients who had 
received T cell depletion, full donor chimerism was reached in both subsets by Day 28. In the 
patient receiving a T replete graft (A8139), T cells were 96% donor and ILCs 91% donor at 
Day 28. This would suggest that even if some ILCs do survive conditioning, within the first 
month post-transplant the majority of these have been replaced (in the peripheral blood) with 
cells of donor origin. Attempts were made to assess chimerism at earlier time points, but it 




Figure 2.10 Graph showing percentage donor chimerism achieved at Day 28. In the two 
patients who had received T cell depletion, full donor chimerism was reached in both subsets 
by Day 28. In the patient receiving a T replete graft, with minimal conditioning chemotherapy 
(A8139), T cells were 96% donor and ILCs 91% donor at Day 28. 
 
 
2.3.9 ILC reconstitution and aGVHD 
Patients were retrospectively divided into two groups: aGVHD Grade 0-I and Grade II-IV, 





















Grade I GVHD was considered with Grade 0 because of the diagnostic difficulties of Grade I 
(especially Stage 1 skin) GVHD. For the purposes of this study, the classical definition of 
acute, i.e. occurring within 100 days of transplant, was used. 
 
Of the 45 patients studied, ten developed Grade II-IV aGVHD. Of these, nine developed 
maximum Grade II (seven skin Stage 3, and two gut Stage 1, skin Stage 1) and one Grade III 
(gut Stage 2, skin Stage 2). Four of these were biopsy proven. 
 
Cell recovery was then considered according to whether or not the patient developed aGVHD 
Grade II-IV or not (Figure 2.11). Perhaps surprisingly, no statistically significant differences 
were seen at any time point for either cell type. Potential confounding factors are considered 





Figure 2.11 Graph showing ILC and CD3+ recovery for all 45 patients. The data were 
analysed according to whether or not the patient developed aGVHD Grade II-IV. No 
significant differences in reconstitution between the groups were seen at any time point for 
either cell type (Mann-Whitney). 
 
 
2.3.10 Potential confounding factors  
Potential confounding factors that might have impacted on recovery, or masked an effect of 
aGVHD were considered. Ciclosporine level at Day 28 did not correlate with either ILC or 



































































Figure 2.12 Ciclosporine levels at D28 were analysed to elucidate if this had an impact on 
ILC or CD3 reconstitution. No correlation was seen between ciclosporine level at Day 28 and 
ILC recovery (r=0.06) or CD3 recovery (r=0.05) (Spearman rank correlation). 
 
The presence or absence of viral reactivation did, however, appear to have a significant effect 
on reconstitution. This was best illustrated by looking at the ratio of CD3 to ILC count. I 
would propose that this is because while either individual value can be affected by degree of 
engraftment, T cell depletion or graft composition, the ratio to some extent compensates for 
this. Figure 2.13 shows CD3/ILC ratio at Day 28 for patients who developed aGVHD Grade 
II-IV, who had reactivation of CMV or EBV to a level where pre-emptive therapy would be 
considered by Day 28 (one exception had a respiratory virus at Day 28) or neither. Only one 
of the patients with GVHD also had viral reactivation (with a CD3/ILC ratio of 57.22). 
Median time to onset of aGVHD for the group shown was 36 days post-transplant. These 
results suggest viral reactivation may mask differences in immune reconstitution related to 
GVHD. Amongst those patients who developed viral reactivation, there was a trend towards 



























Figure 2.13 The impact of viral reactivation post transplant on cell recovery was investigated 
as another potential confounding factor. A comparison of CD3:ILC recovery for patients who 
developed Grade II-IV aGVHD, viral reactivation or neither is shown. A statistically 
significant difference is seen between those with viral reactivation vs neither p=0.02 (Mann 
Whitney). The differences between the other groups were not significant.  
 
 
2.3.11 ILC recovery and IL-22 
As this project was interested in the role of ILCs and IL-22, I explored the relationship 
between ILC recovery at Day 28 and serum IL-22 concentration (Figure 2.14). Red dots 
represent patients who already have aGVHD at this point, blue will go on to develop aGVHD, 
black never develop aGVHD.  
 
 
Figure 2.14 Relationship between ILC recovery and serum IL-22 at Day 28. Red dots 
represent patients who already have Grade II-IV aGVHD at this point, blue will go on to 
develop aGVHD Grade II-IV. No correlation between ILC recovery and serum IL-22 
concentration was seen. High serum IL-22 levels may be associated with aGVHD, but further 







































As discussed above, data shown is for total ILCs, not ILC3s, but the data shown does not 
suggest any correlation between ILC recovery and serum IL-22 concentration. There is, 
however, a suggestion of elevated serum IL-22 in patients who have, or will develop, 
aGVHD. This is discussed further in Chapter 3. 
  
2.3.12 IL-7 homeostasis post HSCT 
Given the difference seen in reconstitution between patients who did and did not receive 
Alemtuzumab and known ILC dependence on IL-7, I investigated the impact of differing T 
cell depletion on serum IL-7 concentration post HSCT. The majority of the first phase of this 
work was performed by Edward Osmund, a BSc student, under my supervision. 
 
In order to try to minimise heterogeneity between the patient groups, and to enable the work 
to be performed within the timeframe his project allowed, 16 patients transplanted between 
August 2014 and September 2016 were retrospectively selected, four in each group, based on 
method of T cell depletion (further clinical details are shown in Table 2.2). Serum IL-7 
concentration was measured at five time-points: admission, Day 0, Day 14, Day 28 and Day 
100 post-transplant, using ELISA as described above. Two patients were subsequently 
excluded from analysis (one due to a serum IL-7 concentration above the upper limit of the 
standard serial dilution, despite 1:10 sample dilution as described, the second due to a 
splenectomy shortly prior to HSCT). 
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If one accepts the hypothesis proposed by Fry et al. (Fry et al., 2001) that IL-7 concentration 
will rise in response to induced lymphopenia, it would be anticipated that serum IL-7 
concentration will rise following conditioning, and that this will be more pronounced the 
more intensive the lymphodepletion. Our data would support this theory – the greatest 
increase in serum IL-7 concentration was seen in the Alemtuzumab 60mg group, and the least 
in the patients receiving a T replete transplant (Figure 2.15). 
 
The normal range quoted by the manufacturer for serum IL-7 is 0.267-9.80pg/ml (mean 
2.51pg/ml) calculated from 32 healthy volunteers. The mean serum IL-7 concentration for all 
patients on admission was just above the quoted normal range (9.9pg/ml), with admission 
concentration highest in the Alemtuzumab 60mg group (17.8pg/ml). Given that the patients in 
this group all had AML, this is likely to represent response to the lymphopenia induced by the 
cycle of chemotherapy given prior to admission, although the Alemtuzumab 30mg group, also 
comprising of four patients with AML, have a mean IL-7 concentration of 4.0pg/ml on 
admission. 
 
The peak in mean IL-7 concentration is seen at Day 14 for all three groups receiving T cell 
depletion, after which it begins to return towards baseline, although the mean concentration 
for all three T cell depleted groups at Day 100 is still above that measured at the time of 
admission. The maximum IL-7 concentration is seen in at Day 14 in the Alemtuzumab 60mg 
group, with a mean concentration of 90.7pg/ml, approximately nine times the upper limit of 
the quoted normal range. 
The T replete group show a very similar rise to that seen in the ATG group between 
admission and Day 0. Rather than continuing to increase, this concentration then remains 
fairly constant until Day 28, and is returning towards baseline by Day 100. 
 
Changes in lymphocyte count represent an almost inverse relationship to IL-7 concentration 
in relation to T cell depletion (Figure 2.15), although with a slight time lag such that by the 
time peak IL-7 levels are reached, lymphocyte recovery is beginning. The nadir was reached 
at Day 0, with lymphocyte recovery beginning by Day 14, with more rapid recovery seen 
initially in those patients who did not receive Alemtuzumab (and whose serum IL-7 
concentration was lower). Many potential confounding factors may also impact T cell 
recovery, including degree of lymphodepletion resulting not just from T cell depleting agents, 
but also from additional conditioning agents, CD3 content of the graft, viral reactivation and 




Figure 2.15 a) IL-7 concentration post HSCT for patients described in table 2.2, grouped by 
method of T cell depletion. Results of 14 patients shown. b) Total lymphocyte count at 
respective time-points (both graphs show mean with SEM). An inverse relationship between 
serum IL-7 concentration and lymphocyte recovery is shown. 
 
 
2.3.13 IL-7, ILCs and GVHD 
I subsequently collected serum samples for IL-7 measurement from patients in Cohort B, to 
enable me to assess the impact of IL-7 on ILC recovery.  
 
 
Figure 2.16 Data shown are for patients in Cohort B a) Peak IL-7 is reached at Day 14, with a 
significant difference between those who did and did not receive Alemtuzumab (p=0.04, 
Mann-Whitney). b) No significant difference in IL-7 concentration is seen at Day 14 for those 




















































































































As with the previous cohort, peak serum IL-7 concentration was reached at Day 14 (Figure 
2.16), with a significant difference between those who did and did not receive Alemtuzumab 
(p=0.04, Mann-Whitney). In contrast to previously published data (Dean et al., 2008), no 
significant difference in IL-7 concentration was seen at Day 14 between those patients who 
subsequently would or would not develop aGVHD (p=0.45, Mann-Whitney). I would propose 
that any differences in IL-7 concentration related to aGVHD in my cohort has potentially 
been masked by the difference seen with Alemtuzumab (none of the patients in the Dean 
study received T cell depletion). 
It has been suggested (Martin et al., 2017) that ILCs are better at utilising IL-7 than T cells. A 
potential relationship between IL-7 concentration and total ILC recovery was therefore 




Figure 2.17 Serum IL-7 concentration and cell recovery at Day 28 is shown. No correlation 
was seen between serum IL-7 concentration and either ILC (a) or CD3 (b) recovery (data 
shown is for patients in Cohort B). 
 
 
No correlation was seen at Day 28 between serum IL-7 concentration and either ILC or CD3 
recovery. The potential for an exponential (one phase decay) relationship was explored, but 
was not found to apply. A difference in count recovery between patients who did and did not 
receive Alemtuzumab had been demonstrated for the whole cohort at Day 28 (Figure 2.9), but 
by Day 28 there was no statistically significant difference in serum IL-7 concentration 
between these two groups. At Day 14, where the difference in IL-7 concentration was 
observed, count recovery was not sufficient for meaningful comparison.  
 
 




























2.3.14 ILCs in donor sources 
Flow cytometry was performed using panel ILCA. Samples from six different donors of bone 
marrow, mobilised PBSCs and cord blood were analysed. ILCs were considered as a 
percentage of live cells and as a percentage of total lymphocytes (Figure 2.18). Numbers are 
small, but, although there appears to be a trend towards an increased ILC content in cord 
blood, no statistically significant differences were seen between donor sources (Kruskall-
Wallis, p=0.58 for live cells and p=0.28 for lymphocytes).  
 
 
Figure 2.18 a) shows the ILC content of different graph sources in relation to live cells, and b) 
in relation to total lymphocytes. Although there is a trend towards increased ILCs in cord 























2.4 Discussion for Chapter Two 
 
This chapter explored ILC homeostasis in human HSCT. Samples were collected from 45 
patients who underwent HSCT at our institution, and analysed using two methods of flow 
cytometry. The two cohorts were then combined for the final analysis. The major benefit of 
this strategy was to increase the total number of patients available for the statistical analysis, 
but it also had the advantage of the data being collected using two different methods. There is, 
however, potential for error in the calculations, due to the use of laboratory counts to derive 
absolute counts.  In addition, due to the different panel used for the Trucount method, I was 
unable to perform ILC subsetting for these patients. Given the small number of circulating 
ILCs, especially in the early post-transplant period, however, I had already found I was 
unable to reliably subset the ILCs at the early time-points post-transplant. The results 
therefore were taken for the whole ILC cohort. I consider this the major weakness in this 
analysis, especially as differential rates of recovery between subsets have previously been 
demonstrated in humans (Munneke et al., 2014). 
 
I have, however, been able to make some interesting and novel observations on the impact of 
T cell depletion on ILCs. Total circulating ILCs were reduced by transplant conditioning, 
with a nadir at Day 0. There was significant inter-patient variability, but early recovery was 
seen by Day 14. By Day 100, the mean count had not reached pre transplant levels.   
 
I have demonstrated CD52 expression by ILCs, in keeping with the finding of Gross et al 
(Gross et al., 2016). It was therefore, perhaps not surprising that a difference was seen in both 
ILC and T cell recovery in patients who received Alemtuzumab versus those who did not. As 
ILCs are predominantly found at the body’s barrier surfaces, it is not possible from this work 
to determine whether Alemtuzumab acts to deplete ILCs in all compartments, or simply in the 
peripheral blood.  
 
Although no statistically significant difference between those patients who received 
Alemtuzumab and those who did not was seen at Day 0 and Day 14, it is interesting that the 
mean ILC count for patients who did not receive Alemtuzumab did not fall to 0. This may 
simply reflect different kinetics between patients receiving ATG, and those receiving T 
replete grafts or errors in detection, but it is worth noting that of the patients in whom 
chimerism was assessed at Day 28, only the patient receiving a T replete graft had not reached 
complete donor chimerism in both the ILC and CD3 compartments. This raises the possibility 
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that some recipient ILCs have survived the conditioning regimen. ILC resistance to 
radiotherapy has previously been demonstrated in a murine model (Hanash et al., 2012). The 
Seattle (T replete) regimen contains minimal chemotherapy (90mg/m2 Fludarabine, in 
addition to the 200cGy TBI), when compared to the majority of other conditioning protocols 
used in our institution, so it may be that similar resistance is being seen. This observation 
warrants further investigation in humans. Given the difficulty of investigating a small 
population of cells in patients who have undergone treatment to further reduce cell numbers, 
especially where these cells are largely defined by absence of expression of antigens, an 
alternative method of investigation, such as mass cytometry (CyTOF) might be preferable. 
 
The main focus of this project was the potential impact of ILCs on the development of 
GVHD. When looking at ILC recovery between patients who did or did not develop Grade II-
IV aGVHD, no statistically significant difference was seen. A number of possibilities exist to 
explain this lack of difference. ILC reconstitution (or at least the ILC population as a whole) 
may not be a factor in the development of aGVHD. It may be that they do play a role, but that 
it is ILCs in the tissues and not in the blood that are important. It may be that they do play a 
role, but that the difference in numbers is masked by a confounding factor. It is worth noting 
that no statistically significant difference was seen in the T cell compartment either, although 
the importance of T cells in aGVHD is well documented. I therefore considered potential 
confounding factors. As discussed, a difference in reconstitution between patients who did, 
and did not receive Alemtuzumab was observed. In addition, a statistically significant 
difference was shown in CD3 to ILC ratio between patients who did and did not develop viral 
reactivation. It is therefore possible that any difference in reconstitution that might impact on 
aGVHD is masked by differences seen as a result of T cell depletion and viral reactivation. 
The heterogeneity of transplant patients makes it very difficult to avoid potentially 
confounding factors. 
 
As this project was interested in a link between ILCs, IL-22 and aGVHD, potential correlation 
between ILC recovery and serum IL-22 was investigated. Again, this is taken with the caveat 
that this is total ILC recovery. There is, however, no evidence that ILC recovery correlates 
with serum IL-22 concentration in this cohort. Of note, the three patients who have already 
developed GVHD at the time-point illustrated all have low ILC counts, raising the possibility 
that GVHD itself reduces the number of ILCs. This has been observed in a mouse model 
(Hanash et al., 2012), where recipient IL-22+ ILCs were significantly reduced in GVHD. It 
was also interesting to note that the four patients with the highest serum IL-22 concentration 
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all had, or subsequently developed, aGVHD. The role of IL-22 in GVHD is discussed further 
in subsequent chapters. 
 
The difference in rate of count recovery observed between patients who did and did not 
receive Alemtuzumab led to further investigation of the role of IL-7 in HSCT. It was 
interesting to document the mirror effect of lymphodepletion and serum IL-7. Although I 
remain unable to determine which of the proposed mechanisms of IL-7 homeostasis is correct 
(increased production in response to lymphopenia, or reduced consumption during 
lymphopenia), the correlation with different methods of T cell depletion is consistent with the 
importance of haematopoietic cells in regulating serum IL-7 concentration (Martin et al., 
2017). I have not here demonstrated an interaction between serum IL-7 and GVHD. 
 
Finally, we had hypothesised that the ILC composition between graft sources might explain 
some of the difference seen in GVHD potential not explained by the differing T cell content 
of different graft sources. Although there was a trend toward an increased ILC content in cord 
blood observed, I have not found a statistically significant difference in the ILC content of the 
graft sources measured.  
 
The main strengths of this work include the relatively large number of patients involved, and 
that regular follow-up samples were obtained. Flow cytometry has been performed using two 
different methods, with comparable results. The major weakness is that I have been unable to 
perform ILC subset analysis. This is in part due to the small numbers of circulating ILCs, 
especially in the early post-transplant period, and also due to the difficulty in isolating cells by 




Chapter 3 The function of IL-22 in graft versus host disease 
 
3.1 Introduction 
3.1.1 IL-22R expression 
In addition to the constitutive expression of IL-22R described in 1.4.1, several groups have 
demonstrated the potential for up-regulation of IL-22R in vitro, in HaCaT cell lines in 
response to IFN-γ (Wolk et al., 2004), in hepatocytes in murine models in response to 
concanavalin (Radaeva et al., 2004), or LPS (Tachiiri et al., 2003) and in human keratinocytes 
in a living skin equivalent model in response to IFN-α (Tohyama et al., 2012). It has also been 
shown that in UVB-irradiated primary human keratinocytes, rIL-22 increases the production 
of pro-inflammatory cytokines (IL-1α, IL-6 and IL-18) (Kim et al., 2017). The same study 
demonstrated an increase in IL-22R expression in the skin of mice and humans irradiated with 
UVB and thus suggests that skin inflammation due to UVB damage is partially due to the 
increased responsiveness to IL-22 of keratinocytes.  
 
3.1.2 STAT1 versus STAT3 response and the role of IFNa 
An increase in plasmacytoid dendritic cells (pDCs), professional Type 1 IFN producing cells, 
has been demonstrated in the gut (Bossard et al., 2012) and skin (Malard et al., 2013) of 
patients with aGVHD. IFN-α has been shown to increase IL-22R expression, as discussed 
above, but also to increase the signal transducer and activator of transcription factor-1 
(STAT1) activating function of IL-22 (Bachmann et al., 2013). Bachmann and colleagues 
have shown in DLD-1 colon epithelial/carcinoma cells that pre-incubation with IFN-α 
resulted in increased STAT1 activation, while having only a minimal effect on STAT3. This 
increase in phosphorylated signal transducer and activator of transcription factor-1 (pStat1) 
was confirmed in primary keratinocytes. It was subsequently demonstrated that this increase 
in pStat1 translated into a significant increase in the mRNA expression of chemokines CXCL-
9 and CXCL-10 when DLD-1 colon epithelial/carcinoma were pre-incubated with IFN-α and 
then stimulated with IL-22. IL-22 alone did not induce CXCL-10. Data on CXCL-10 mRNA 
production correlated well with protein production. CXCL9, CXCL10 and CXCL11 are the 
ligands of the receptor CXCR3, expressed mainly by activated or memory CD4+ and CD8+ T 
cells. This axis is known to be upregulated in inflammation (Flier et al., 2001, Schroepf et al., 
2010, Marshall et al., 2017).  Thus in the presence of IFN-α, IL-22 may contribute to the 
maintenance of a Th1 signal. pDCs have also been shown to increase differentiation towards a 
Th22 phenotype in vitro (Duhen et al., 2009). A combination of the mechanisms described 
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above has the potential to create a positive feedback loop, sustaining an inflammatory 
response. 
 
3.1.3 IL-22 deficient T cells and SCT  
The potentially detrimental role of donor derived IL-22 was briefly alluded to in Chapter 1. 
Two papers using murine models have explored the impact of donor-derived IL-22 on 
GVHD.  Couturier et al (Couturier et al., 2013) report reduced aGVHD mortality and a 
reduction in histopathological grade of GVHD in the skin and colon of mice receiving IL-22-/- 
T cells when compared to wild type, with the gut scores when the IL-22-/- donors were used 
being comparable to syngeneic T cells. In addition they show that recipients of IL-22-/- cells 
have an increased proportion of CD25+ Foxp3+ Tregs at Day 6 post HSCT when compared to 
wild type recipients (with no difference in the Treg content of the graft). In a series of 
experiments using CD25-depleted T cells in both IL-22-/- and wild type donors they 
demonstrate that, in the absence of IL-22, both the conversion of naïve CD4+ CD25- T cells 
into Tregs and the expansion of existing Tregs appear to be more effective (the mechanism, is 
unclear – Tregs do not express IL-22R). Looking at the inflammatory response in the first 
week post HSCT, the recipients of IL-22-/- T cells have a reduction in plasma levels of TNF-α, 
IFN-γ and MCP-1 (monocyte chemoattractant protein 1). Looking at specific target organs, in 
the small intestine there was a reduction in IFN-γ, and the chemokines CXCL9, CXCL10 and 
CXCL11. In the skin there was a reduction in expression of β-defensin 3 and calthelicidin. 
These results suggest (donor) IL-22 deficiency may protect against GVHD through both 
reduction in recruitment of effector cells and an increase in Tregs. Importantly, they were also 
able to demonstrate that the GVL effect was preserved. The authors state that they did not 
observe any non T cell source of IL-22, but they are not able to exclude the presence of radio-
resistant ILCs. 
 
Further work (Lamarthee et al., 2016a) showed that at seven days post-transplant, pSTAT-1 
was higher in the gut of recipients of wild type than IL-22-/- T cells. In vitro they demonstrate, 
like Bachmann et al (Bachmann et al., 2013), that cxcl10 mRNA is significantly induced in 
the presence of IFN-α and IL-22, when compared to either alone. This effect was lost in the 
presence of the JAK1/2 inhibitor Ruxolitinib. In a minor HA mismatched mouse model, with 
IFNAR-/- (IFN receptor deficient) recipients and wild type and IL22-/- donors, it was shown 
that only a combination of IFNAR-/- and IL22-/- donor T cells resulted in a statistically 
significant reduction in intestinal barrier destruction (as shown in a FITC-dextran model). 
These mice also had reduced circulating levels of IFN-α and IFN-γ. In a group of patients, 
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with and without GVHD, there was increased pSTAT1 and CXCL10 in the gut biopsies of 
those with acute GVHD, suggesting the previous findings are also relevant in humans. The 
model proposed by the authors is that pDCs secrete IFN, and activated donor T cells produce 
IL-22. These activate STAT-1, resulting in increased CXCL10 secretion from the intestinal 
epithelial cells. In turn this induces increased infiltration by Th1 cells, thus increasing GVHD. 
 
3.1.4 Cytokine polymorphisms 
The Hardy-Weinberg equilibrium, described separately by Hardy and Weinberg in 1908, 
states that, “in the absence of migration, mutation, natural selection, and assertive mating, 
genotype frequencies at any locus are a simple function of allele frequencies” (Wigginton et 
al., 2005). Cytokine polymorphisms present a way of indirectly investigating the involvement 
of a particular cytokine on the development of a specific condition. A number of 
polymorphisms have already been demonstrated to impact on the development of GVHD 
(Dickinson and Holler, 2008, Goussetis et al., 2011, Masetti et al., 2015, Broen et al., 2011, 
Middleton et al., 1998).  
 
3.1.5 IL-22 polymorphism in disease 
Polymorphisms of IL-22 have been shown to associate with a variety of malignant, 
inflammatory and infective conditions, including ulcerative colitis (Chi et al., 2014), gastric 
mucosa-associated lymphoid tissue (MALT) lymphoma (Liao et al., 2014), non-small cell 
lung cancer (NSCLC) (Liu et al., 2014), gastric cancer (Qin et al., 2015) and hepatitis C 
(Hennig et al., 2007). Some groups have gone further, to try to establish a functional reason 
for this difference. In the study on gastric MALT lymphoma, for example, PBMCs from 
patients with ten versus two risk alleles were co-cultured with H. pylori (a known risk factor 
for gastric MALT lymphoma). Difference in IL-22 production was not significantly different, 
although there was a trend towards lower production with the increased number of risk 
alleles. In the Liu study of 324 individuals, using a case-control design, a CT genotype at 
rs2227484 (a nearby variant of rs2227485) showed an odds ratio of 1.9 for NSCLC when 
compared to a CC genotype (p=0.038). Plasma levels of IL-22 were subsequently measured. 
Plasma IL-22 was significantly increased in patients with NSCLC compared to healthy 
controls, and also for patients with advanced compared to early stage disease. When the IL-22 
levels were compared by genotype, no statistically significant difference was seen between 
genotypes in the control group, but higher plasma IL-22 levels were observed for the CT 
compared to CC genotype for patients with NSCLC. 
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3.1.6 Normal range for IL-22 
No standardised reference range for serum IL-22 in healthy individuals has been established 
(details of control values given with the ELISA used in this project are discussed in section 
3.2.4). Different groups have published healthy control values for comparison with the group 
under investigation. These published ranges vary quite widely; Median 4.6pg/ml (range 4.6-
4.6pg/ml) (de Oliveira et al., 2015), 12.58 +/- 12.59pg/ml (Meephansan et al., 2011), 20+/- 
13pg/ml (Ruggeri et al., 2014) and mean 67.45pg/ml (da Rocha et al., 2012). Common to all 
of these studies, however, is an increase in serum IL-22 in the study group (rheumatoid 




3.1.7 Questions for Chapter 3 
 
Having proposed that ILC derived IL-22 protects target organs from GVHD, this chapter aims 
to further analyse the IL-22 axis in GVHD. Specific questions addressed are listed below. 
 
1. How does transplant conditioning therapy (full and reduced intensity) impact on IL-22 
expression? 
 
2. Is there evidence for a change in IL-22 expression in GVHD? 
 
3. Are ILCs responsible for the IL-22 signature in cutaneous GVHD? 
 
4. Is expression of the IL-22R altered during GVHD? 
 
5. Does IL-22 gene polymorphism impact on incidence or outcome of GVHD? 
 
Aims: 
1. To use a combination of gene expression data and ELISA to explore the impact of 
conditioning therapy on IL-22 expression in skin and serum 
 
2. To use the same methods to explore IL-22 expression in GVHD 
 
3. Using flow cytometry, to investigate the ILC population in the skin in GVHD, and to 
determine whether these cells are the source of IL-22 
 
4. Using immunohistochemistry, to explore expression of the IL-22 receptor in GVHD 
 
5. To explore the impact of a single nucleotide polymorphism for the IL-22 gene on the 







3.2 Methods for Chapter three 
3.2.1 Sample collection 
Skin samples in this chapter came from two sources. Healthy skin used was surplus tissue 
obtained from plastic surgery, primarily breast and abdominal surgery. Ethical approval for 
samples from healthy donors was granted by the NRES Committee North East – Newcastle & 
North Tyneside 1 (17/NE/0361). Where skin samples were from patients undergoing HSCT, 
shave biopsies were taken either specifically for research purposes, or, where the patient had a 
rash suggestive of GVHD, material excess to that needed for diagnostic purposes was taken 
from clinical samples. Ethical approval for patient samples was granted by the NRES 
Committee North East – Newcastle & North Tyneside 2 (14/NE/1136). 
 
Serum sample collection and storage is described in 2.2.1 and 2.2.10. 
 
DNA samples were obtained from the EuroTransplantBank repository. All patients consented 
for sample collection and molecular testing. The project was approved by the Newcastle and 
North Tyneside 1 Research Ethics Committee, and the Ethics Committee of the University 
Hospital, Regensburg, Germany. Correlative clinical data were obtained from the 
EuroTransplantBank database (www.eurotransplantbank.org). 
 
3.2.2 Media and buffers 
Details of media and buffers used in this chapter are provided in Appendix 2. 
 
3.2.3 Nanostring 
NanoString nCounter allows the detection of mRNA gene expression without the need for 
pre-amplification, thereby removing potential pre-amplification bias. Genes of interest are 
multiplexed with fluorescently labelled probes, and can then be read by a computerised 
optical lens. The panel used in this study was the 579 probe NanoString Human Immunology 
V2TM code set. 
 
Skin biopsies were lysed in RLT lysis solution (RLT lysis buffer, Qiagen) with 1% 2-
mercaptoethanol (Sigma Life Science), and then homogenised using a 21g needle. Samples 
were stored at -800C. 
 
For the full intensity and GVHD samples, 150ng of RNA was used, with samples made up to 
10µl using nuclease free water. 250ng of RNA, made up in 5µl of nuclease free water was 
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used for the reduced intensity samples. Hybridised mRNA was captured using a NanoString 
cartridge and Prep Station. The cartridge was screened using a NanoString Digital Analyser at 
550 fields of view. 
 
Raw NanoString data was collected and normalised using the Nanostring nSolver v3.0 
software. Analysis was then performed using nSolver Advanced Analysis, allowing for 
differentially expressed genes to be revealed. P-values generated by a two-tailed test were 
adjusted using the Benjamini-Hochberg false-discovery rate (FDR). Quality control (QC) 
removed genes that did not pass this check, allowing for generation of volcano plots using the 
'ggplot' package in RStudio. Work up to, and inclusive of, the generation of volcano plots was 
performed by A Resteu, with the assistance of L Sayer (an MSc student in our laboratory). 
Further interpretation of the results was performed by myself. 
 
3.2.4 IL-22 quantification  
IL-22 quantification was performed using a human IL-22 Quantikine enzyme-linked 
immunosorbent assay (ELISA) Kit (R&D systems). The assay was performed according to 
the manufacturers instructions. Briefly, a dilution series was produced using the human IL-22 
standard provided. 100µl of standard or control were placed in each well of a 96 well plate 
and incubated for two hours at room temperature. Each well was washed four times with wash 
buffer and 200µl of human IL-22 conjugate was added to each well. The plate was then 
incubated for a further two hours at room temperature. Each well was then washed a further 
four times, after which 200µl of substrate solution was added per well. The plate was 
incubated for a further 30 minutes in the dark at room temperature. 50µl of stop solution was 
then added per well, and the optical density was measured using a microplate reader 
(Multiskan Ascent, Thermo Labsystems, Thermo Fisher Scientific), set at 540nm and 450nm.  
To calculate the values, the readings at 540nm were subtracted from those at 450nm. All 
values were log transformed, and non-linear regression was performed using GraphPad Prism 
(version 7).  
 
The mean minimum detectable dose of the assay is reported to be 2.7pg/ml. The product 
datasheet reports 53 serum IL-22 concentrations. Of these only 4% are detectable, with a 





3.2.5 Mononuclear cell isolation from skin biopsies 
Skin shave biopsies were cut into fragments measuring approximately 1mm x1mm. These 
were placed in RF-10 with 1:100 collagenase and incubated overnight at 370C in a 
humidified, 5% CO2, 95% air incubator. After 16-18 hours, the sample was dissociated using 
a pipette, filtered through a 100µl filter and washed with PBS. Total cell count was estimated 
using a 1:1 dilution with trypan blue exclusion dye (Invitrogen) on an Improved Neubauer 
Haemocytometer (Weber Scientific International).  
 
3.2.6 Flow cytometry  
For extracellular staining, cells were processed as above, then re-suspended in 50µl flow 
buffer. 4µl anti-mouse IgG (Sigma Aldrich) was added to the sample and incubated for 4 
minutes. Antibodies were then added as per panels ILCA and ILCB, as described in 2.2.6. and 
incubated at 4oC in the dark for 30 minutes. The cells were washed in flow buffer (500g for 5 
minutes) and re-suspended in 200µl flow buffer.  4,6-diamidino-2-phenylindole (DAPI, 
Partec) was used to exclude dead cells. 
 
For intracellular staining, cells were processed as above, then placed in 1ml of RF-10, in a 
flat-bottomed 24 well plate, at a concentration of 1x106/ml (stimulated, unstimulated, isotype 
controls). Starting from a published protocol (Withers et al., 2016), and titrating 
concentrations and duration of incubation, stimulation was with 25ng/ml PMA and 
1000ng/ml Ionomycin (Sigma Aldrich) for four hours, with 10µl /ml Brefeldin A (Sigma 
Aldrich) added at one hour. Cells were then transferred to a 96 well V bottomed plate, washed 
twice with PBS and re-suspended in 100µl zombie acqua (BioLegend®)/well. After staining 
for 20 minutes in the dark, cells were washed with RF-10 and re-suspended in surface 
stains/flow buffer. Cells were stained for 30 minutes in the dark at 40C. Cells were then 
washed, and incubated for 20 minutes at 400C in Fixperm (BD, Biosciences), after which they 
were washed twice and re-suspended in intra-cellular stains/Perm buffer (BD, Biosciences). 
Cells were stained for 30 minutes in the dark at 40C. Cells were washed twice with Perm 
Buffer, re-suspended in flow buffer and transferred to FACS tubes (BD, Biosciences). 
 
3.2.7 Immunohistochemistry 
IL-22 receptor staining was performed by the Molecular Pathology Node, Newcastle upon 
Tyne Hospitals NHS Foundation Trust. Staining for the antibody had previously been 
optimised within the department. The antibody used was IL-22 R alpha 1 Antibody, NBP2-
38496, Novus Biologicals, at a concentration of 1:750. Staining was performed on a 
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Discovery IHC machine (Ventana). Positive cells were counted by two blinded, independent 
assessors. Images were taken with an Axio Imager microscope (Zeiss). 
 
3.2.8 SNP selection and processing 
A literature review identified IL-22 single nucleotide polymorphisms (SNPs) that had been 
previously shown to be associated with malignancy, infection and auto-immune disease. Ten 
common polymorphisms of IL-22 are known, of which eight are within a block having high 
linkage disequilibrium (Weger et al., 2009). One SNP within this block (rs2227485), which 
has also been linked to ulcerative colitis (Chi et al., 2014), gastric mucosa-associated 
lymphoid tissue lymphoma (Liao et al., 2014) and papillary thyroid cancer (Eun et al., 2013) 
was identified as a potential candidate for investigation (Figure 3.1). Located in the promoter 
region (Eun et al., 2013, Hu et al., 2014), the allele distribution in the population is almost 
equal, with a minor allele frequency of 0.4846 (dbSNP, 1000 genomes). Published functional 
studies have shown the TT genotype of this SNP to correlate with high levels of IL-22 (De 




Figure 3.1 A graphical representation of the IL-22 gene. The SNP rs2227485 is located in the 
promoter region, 429 base pairs upstream of the transcription start site. 
 
 
Donor and recipient DNA samples from two transplant centres that use the 
EuroTransplantBank repository (Northern Centre for Bone Marrow Transplantation, UK and 
University Hospital Regensburg, Germany) were outsourced to LGC Genomics Ltd for SNP 
typing at rs2227485. The company use KASPTM genotyping, using competitive allele-specific 
PCR, which allows bi-allelic scoring of SNPs at pre-determined loci. The overall clinical 







aGVHD grade was diagnosed by the patients’ clinicians, in accordance with the modified 
Glucksberg criteria (Glucksberg et al., 1974, Przepiorka et al., 1995). 
 
3.2.9 SNP Study, statistical analysis  
Kaplan-Meier survival curves were plotted, and the differential survival between the CCTT 
group and other genotypes was compared using the log-rank test. 
The impact of the chimeric genotype on (i) incidence of death due to GVHD, and (ii) 
incidence of non-relapse mortality, was assessed using the semiparametric proportional 
hazards regression model proposed by Fine and Gray (Fine and Gray, 1999) via a competing 
risks analysis as implemented by Scrucca et al., (Scrucca et al., 2007, Scrucca et al., 2010) 
which allows for multivariate assessment of clinical covariates in the model. The competing 
risk for (i) death due to GVHD is death due to relapse or other non-relapse, non-GVHD 
causes; and the competing risk for (ii) non-relapse mortality is relapse. 
 
The impact of the chimeric genotype on incidence of aGVHD (Grade II-IV) was assessed by 
fitting a logistic regression model. Simple univariate statistical analyses were used to screen 
potential clinical factors for inclusion in the regression model. A p-value of 0.2 was used for 
the χ2 tests, and the following factors were identified as possible confounding variables: 
underlying disease (leukaemia or other), stem cell source (bone marrow or peripheral blood), 
Centre (Newcastle or Regensburg), donor match (matched unrelated or other), whether the 
patient had a “female to male” transplant or not, whether donor and/or recipient were CMV 
positive or not, time of transplant (before or after 2005), conditioning intensity (reduced 
intensity or not), and whether the transplant was T-cell replete or depleted. A stepwise 
procedure minimising the Bayesian Information Criteria (BIC) (Schwarz, 1978), and checking 
that all terms were significant in the model, was used to select the best regression model. 
 
Statistical software R, version 3.5.1 (http://www.r-project.org/) and JMP®, Version 13 (SAS 
Institute Inc., Cary, NC, 2016) were used for the computations. The R function CumIncidence 
(based on package cmprsk) and package crr were used to estimate cumulative incidence 
curves. 
 




3.3  Results 
3.3.1 IL-22 induction in conditioning 
It has been proposed that the mechanism by which recipient IL-22 is protective in SCT is 
through its induction during transplant conditioning, lessening target organ damage, thus 
reducing activation of APCs and so limiting phase one of the three phase model of GVHD. 
This theory of protective IL-22, however, is based on the findings of a mouse model, where 
transplant conditioning was performed with irradiation alone, to which ILCs have been shown 
to be resistant, and where recipient ILCs persist at three months post-transplant. In addition, 
the differences noted in pathology were observed in the gut and liver, but not the skin 
(Hanash et al., 2012). To my knowledge, the response of IL-22 in humans post-transplant 
conditioning has not been documented, but it has previously been shown that circulating 
human ILC3s are primarily of donor origin by seven weeks post-transplant (Munneke et al., 
2014). I therefore investigated the response of IL-22 to conditioning in humans undergoing 
full or reduced intensity conditioning. 
 
3.3.2 Full intensity 
Paired skin biopsies were taken on admission and Day 0 from six patients undergoing SCT 
for acute lymphoblastic leukaemia. All received conditioning with cyclophosphamide, total 
body irradiation and Alemtuzumab (either 30mg or 60mg). Further clinical details are shown 
in Table 3.1. One admission sample was excluded from analysis after not passing QC 
measures. Differential gene expression between the two time-points was analysed using 
NanoString technology. 348 genes showed differential expression between admission and 
Day 0, illustrated in the volcano plot in Figure 3.2. Those with a positive fold change showed 
increased expression in the Day 0 skin when compared to the admission sample. The genes 
with a Benjamini-Hochberg adjusted p value of less than 0.05 are shown in black. Neither IL-
22 nor IL-22R are shown, as they did not meet the QC measures of the nCounter advanced 
analysis module. Genes that do not achieve a minimum number of counts in at least half of 
the samples are filtered out by the software and omitted from the differential expression 
analysis. This was the case for IL-22 in all of the following analyses. The genes showing the 
greatest up-regulation, CUL9 (log2 fold change (FC)=1.88), BAX (log2 FC=1.8), TNFRSF10 
(log2 FC=1.89) and CDKN1A (log2 FC=1.54) have all been previously linked to DNA 
damage and cell death (Li and Xiong, 2017, Oltvai et al., 1993, Sheikh et al., 1999, Hussain et 
al., 2017). Down-regulation of the IL-2Rβ may simply reflect the reduction in leucocytes seen 
at the end of conditioning. There is, perhaps, less up-regulation of inflammatory cytokines 
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than might be expected. It would be interesting to compare these findings in the skin with 
other target organs of aGVHD. 
 
Serum IL-22 concentration was also compared for four patients undergoing full intensity 
conditioning on day of admission and Day 0. Three patients received cyclophosphamide and 
TBI (with or without Alemtuzumab) and one TBI alone (myeloablative haploidentical 
protocol). IL-22 concentration was measured using ELISA, as detailed in 3.2.4. No significant 
difference was seen between pre and post conditioning samples (p= 0.875, Wilcoxon signed 
rank test), with IL-22 concentration on day of admission ranging from undetectable to 
12.8pg/ml, and on Day 0 from undetectable to 14.4pg/ml, with a median value of 7.0pg/ml 
and 7.8pg/ml respectively (Figure 3.3). The reason why the levels at both admission and Day 
0 are slightly higher in the full intensity than the reduced intensity group is not clear, but all 
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Figure 3.2 Genes differentially expressed between admission and Day 0 from skin biopsies of 
six patients receiving full intensity conditioning. Genes showing an increased fold change 
were up-regulated post conditioning. Those shown in black showed have an adjusted p-value 
of <0.05. The genes showing the greatest up-regulation have been previously linked to DNA 




Figure 3.3 No statistically significant change was seen in the serum IL-22 concentration 
between admission and Day 0 for patients receiving full intensity conditioning. 
 









































3.3.3 Reduced intensity 
Using the same techniques, paired skin biopsies were taken from six patients undergoing 
reduced intensity conditioning with Fludarabine, either Melphalan or Busulphan and 
Alemtuzumab. Indication for SCT was acute myeloid leukaemia (5), acute lymphoblastic 
leukaemia (1) and Hodgkin lymphoma (1). Two admission samples were excluded from the 
analysis as they did not pass the QC measures. 381 genes were found to be differentially 
expressed, when comparing admission samples to Day 0. The IL-22R had a log2 fold change 
of 0.165, but with a p value of 0.996. The most interesting finding was the lack of a 
statistically significant difference in expression of any gene following reduced intensity 
conditioning (Figure 3.4). Potential explanations for this include sample size or timing of the 
biopsy (it is possible, for example, that the maximal impact of conditioning is seen at a later 
time point), but absence of a ‘damage’ signal calls into question the applicability of the 
conditioning induced tissue damage as the first step in the development of aGVHD in reduced 
intensity conditioning. 
 
Paired serum samples from five patients undergoing reduced intensity conditioning (further 
details in Appendix 1) were also tested for IL-22 concentration on admission and Day 0. 
Admission values ranged from undetectable to 3.9pg/ml, and Day 0 from undetectable to 
2.6pg/ml (p=>0.99, Wilcoxon signed rank test). The median value was undetectable on both 







Figure 3.4 Genes differentially expressed between admission and Day 0 from skin biopsies of 
six patients receiving reduced intensity conditioning. Genes showing an increased fold change 





Figure 3.5 No statistically significant change was seen in the serum IL-22 concentration 
between admission and Day 0 for patients receiving reduced intensity conditioning. 
 



































3.3.4 IL-22 induction in GVHD 
Having found no evidence of IL-22 induction during conditioning, I next investigated whether 
IL-22 levels were elevated in GVHD. 35 skin biopsies were initially analysed, 22 with GVHD 
meeting the histopathological criteria for Grade 2+ (‘Grade 2+’), seven performed as possible 
GVHD, but not histopathologically confirmed (‘rash’) and six healthy controls (‘HC’). Four 
of the patient biopsies were removed for clinical reasons (onset too late for acute GVHD, and 
not post DLI) and two samples did not meet QC requirements. Clinical details for the samples 
in the final analysis are shown in Table 3.1. Samples were analysed twice, comparing ‘Grade 




Figure 3.6 Volcano plot showing differential gene expression between GVHD (Grade II-IV) 
and healthy controls (skin biopsies). Genes shown in black showed a statistically significant 
change in expression (adjusted p-value of <0.05). The greatest up-regulation was seen in 
ligands of the chemokine receptor CXCR3. 
 
 
In the comparison of GVHD versus healthy controls (Figure 3.6), the greatest up-regulation in 
the GVHD samples is seen in CXCL10 (Log2 FC=6.45), CXCL9 (Log2 FC=5.98) and 
CXCL11 (Log2 FC=5.52), all ligands of the chemokine receptor CXCR3, and known to be 
























induced by STAT1 (Kanda and Watanabe, 2007). These findings are consistent with the 
increase in STAT1 signalling seen in the gut of patients with aGVHD (Lamarthee et al., 
2016a), and in this experiment a 2.51 Log2 FC was seen in STAT1 (p=0.0004). It is not 
possible to tell from this analysis what is driving the STAT1 pathway, but there is greater 
increase in IL22RA2 (Log2 FC=1.81, p=0.01), and IL-10RA (Log2 FC=1.16, p=0.01) than in 
the interferon receptors IFNAR1 (Log2 FC=-0.376, p=0.08), IFNAR2 (Log2 FC=1.06, 
p=0.0008) and IFNGR1 (Log2 FC=0.385, p=0.03).  
 
The three genes with the most significant difference in expression, and a Log2 fold change of 
greater than two were ICAM (intercellular adhesion molecule) 1, ICAM2 and SOCS3 
(suppressor of cytokine signalling 3). ICAM 1 has been previously shown to be upregulated 
in the gut, liver and skin in a murine model of GVHD (with a non-significant small increase 
of ICAM 2 in the skin only) (Eyrich et al., 2005). Given its importance in T cell activation, 
and interaction between leucocytes and endothelial cells, this is perhaps not surprising. The 
SOCS genes, however, are involved in negative feedback of cytokine signalling. The increase 
in SOCS3 seen here, therefore, seems a logical response to the cytokine production seen in 
GVHD. A previous study using qRT-PCR, however, showed a reduction in SOCS3 in the 
mononuclear cells of patients with aGVHD (and post HSCT without GVHD) when compared 









Figure 3.7 Volcano plot showing differential gene expression between GVHD (Grade II-IV) 
and GVHD Grade 0 (skin biopsies). Less differential gene expression is seen than when the 
comparison is healthy controls, with none reaching statistical significance. 
 
 
As would be anticipated, there is less differential gene expression when comparing GVHD 
with other inflamed skin samples (Figure 3.7) than when the comparison group is healthy 
controls. The antimicrobial peptide DEFB4A (beta-defensin 4A) has the greatest fold increase 
in GVHD (Log2 FC 2.63), followed by the calcium binding proteins S100A8 and S100A9, 
although these do not reach statistical significance. There is slight down regulation of 
IL22RA, although this does not reach statistical significance (Log2 FC -0.34, p=0.88). 
 
In the serum, a significant increase (p=0.0054, Kruskal-Wallis) in IL-22 concentration was 

























Figure 3.8 Serum IL-22 levels in healthy controls versus patients with GVHD, versus post-
transplant controls (at Day 14, 28, 56 and 100). A significant increase in IL-22 concentration 
is seen in the serum of patients with GVHD (p=0.0054, Kruskal-Wallis). 
 
 
The presence of increased serum IL-22 in patients with GVHD still does not answer the 
question as to whether the elevated IL-22 is contributing to the GVHD, or is part of the 
body’s mechanism for defence and repair. For Cohort B, serum samples had been collected at 
all time points in addition to the EDTA samples, allowing the timeline to be analysed. Figure 
3.9 illustrates serum IL-22 concentration over time for the three patients who developed 
Grade II-IV GVHD, compared to the mean of the remaining 17 patients in the cohort. One 
Day 100 serum has been excluded from the group, as a significant outlier. In all three patients 
with GVHD a rise in IL-22 concentration is seen. It is interesting to note that in two of the 
three patients who developed GVHD, serum IL-22 concentration appears to have peaked, 
prior to the development of clinically apparent GVHD. None of the three patients had either 



































Figure 3.9 Timelines for the three patients who developed GVHD in Cohort B, compared to 
the mean of the other 17 patients (error bars show SD). In all three patients, a rise in serum 
IL-22 concentration is seen. In two of the three patients, this rise predates the development of 
clinically apparent GVHD.  
 
 
3.3.5 Are ILCs responsible for IL-22 production in GVHD? 
Published data show an increase in CD4+, IL-22 producing cells in the skin of patients with 
aGVHD compared to healthy controls, in addition to increased IL-22 mRNA expression in 
lesional biopsies (Bruggen et al., 2014). Whether the downstream effect of IL-22 is pro-
inflammatory, or intended to reduce damage, is not however established. In addition, rapid 
reconstitution of NCR+ ILC3, cells able to produce IL-22, in the peripheral blood of patients 
post SCT correlated with a reduction in the risk of GVHD development (Munneke et al., 
2014).  This study looked only in the peripheral blood. I therefore wished to investigate 
whether ILCs were increased in the lesional skin of patients with GVHD, and whether they 
were producing IL-22.  
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Three flow cytometry panels were used, described in 3.2.6, two with extracellular markers 
only (ILCA and ILCB), the third an intracellular panel, allowing staining for IL-4, IL-17, IL-
22 and IFN-γ. Looking first at the extracellular panels, healthy control samples were 
compared to lesional samples that were subsequently histopathologically confirmed as 
GVHD. In addition, biopsies taken for GVHD diagnosis that were not diagnostic of GVHD 
were used as post-transplant controls. A total of 12 samples were analysed for extracellular 
markers only. Whether expressed as a proportion of lymphocytes (data not shown) or as a 
proportion of live cells (Figure 3.10), there was no evidence for an increase in the Lin-127+ 
ILC population in GVHD, when compared either to control or post-transplant non-GVHD 
samples (p=0.68, Kruskal-Wallis). 
 
 
Figure 3.10 a) Example of gating strategy for ILCs from skin biopsies. b) ILCs isolated from 
skin biopsies from healthy controls, patients with GVHD, and non-diagnostic samples (gated 
on live singlets), as a proportion of live cells. No significant difference is seen between the 




































Simultaneous work looked to identify which cells were producing IL-22. Phorbolmyristate 
and ionomycin (Sigma Aldrich) stimulation, was used to investigate cytokine production by T 
cells and ILCs from healthy skin. IL-17 production by both subsets was demonstrated, in 
addition to IL-22 production by T cells, but not by ILCSs (Figure 3.11).  
 
 
Figure 3.11 An example of the gating strategy used (gated on live single cells) for the 
intracellular staining protocol. IL-22+ and IL-17+ T cells can be seen. A small number of IL-
17+ ILCs, but no IL-22+ cells, are seen. 
 
When isolating cells from the much smaller fragments of excess material from diagnostic skin 
biopsies, the starting number of events was far fewer than from healthy skin. Figure 3.10 has 
illustrated that there was no evidence for an increase in Lin-127+ cells in the skin of patients 
with GVHD. I have, therefore, not been able to isolate sufficient Lin-127+ cells from 
pathological samples to comment on IL-22 production by ILCs in GVHD. 
 
3.3.6 The IL-22 receptor in GVHD 
The role of IL-22R up-regulation in UVB induced skin damage has been discussed in 3.1.1. 
Given the apparent increase in IL-22 observed in GVHD, the NanoString results, and the 
previously discussed ability of inflammatory signals to up-regulate expression of the IL-22R, 
I further investigated IL-22R expression in GVHD skin biopsies. 
 
15 samples were stained for the IL-22R, with examples shown in Figure 3.12. Five had a 



















immunosuppression), five biopsies were taken where the patient had a rash suggestive of 
GVHD, but had a histopathological grade of 0 (although two were subsequently felt clinically 
to evolve to GVHD) and five were healthy controls. Biopsies were scored as the number of 
positive cells out of 100 (Figure 3.13). 
 
Minimal variation was seen amongst the healthy controls. While significant variation was 
seen amongst both pathological groups, there was an increase in IL-22R expression for 
pathological samples in comparison to the healthy controls, with the median percentage of 
positive cells being six in the control group and 28 in the GVHD group (p=0.03, Mann-
Whitney U). The two patients who were subsequently felt to evolve to GVHD had scores of 
11 and 28. The relatively greater increase seen for IL-22R staining, when compared to the 
results of the gene expression data probably relates to exactly what is being examined. When 
looking at the IL-22R staining, the proportion of positive cells along the dermal-epidermal 
junction only was considered. The gene expression data was taken from digested whole skin 
shaves. 
 
a)           b) 
 
 
Figure 3.12 Examples of IL-22R staining in a) healthy control, b) GVHD. A clear increase in 





Figure 3.13 % of IL-22R positive cells along the dermal-epidermal junction. An increased 
level of IL-22R expression is seen in the pathological specimens, compared to the healthy 
controls. This difference reached statistical significance (p=0.03, Mann-Whitney U). 
 
 
3.3.7 Impact of IL-22 polymorphism on GVHD risk 
As has previously been discussed, murine models have shown that the role of IL-22 in GVHD 
differs depending on whether the IL-22 is produced by the donor or recipient. A summary of 
these findings is shown in Table 3.2. While IL-22 production by the recipient appears 
































































































In addition, it has been shown that the TT genotype at rs2227485 correlates with increased IL-
22 production in vaginal fluid in humans (De Luca et al., 2013), Figure 3.14. It was therefore 
hypothesised that a transplant from a TT donor into a CC recipient would result in increased 
GVHD and reduced survival.  
 
 
Figure 3.14 Cytokines (pg/mg, cytokine/total proteins (mean values +/- SEM) in the vaginal 
fluids of women bearing the CC, CT or TT genotypes at rs2227485 in IL22. Taken from De 
Luca et al IL-22 and IDO1 Affect Immunity and tolerance to Murine and Human Vaginal 
Candidiasis, PLOS Pathogens (2013). 
 
 
Genotype information at rs2227485 was available for a total of 524 transplants. Patient 
baseline characteristics are shown in Table 3.3. The mean patient age was 46.3 years. 
Approximately two thirds of the transplants were T cell depleted and two thirds received 
reduced intensity conditioning. 57% of grafts were from matched unrelated donors and 76% 





Table 3.3 Patient characteristics, SNP study  
Other& CCTT& Total&
10#Year#Status# Alive# 30# 0# 30#
Dead# 219# 17# 236#
LtF# 246# 12# 258#
Total# 495# 29# 524#
T#cell#deple@on# Replete# 158# 6# 164#
Depleted# 337# 23# 360#
Total# 495# 29# 524#
Donor# Sib/Other# 214# 9# 223#
MUD# 281# 20# 301#
Total# 495# 29# 524#
Transplant#Date# Before#2005# 124# 4# 128#
AKer#2005# 371# 25# 396#
Total# 495# 29# 524#
Female#to#Male# Not#F#to#M# 405# 23# 428#
F#to#M# 89# 4# 93#
Total# 494# 27# 521#
Condi@oning# Myeloabla@ve# 142# 7# 149#
RIC# 353# 22# 375#
Total# 495# 29# 524#
Stem#cell#source# PBSC# 372# 23# 395#
Other# 122# 5# 127#
Total# 494# 28# 522#
Transplant#Centre# Regensburg# 290# 18# 308#
Newcastle# 205# 11# 216#
Total# 495# 29# 524#
CMV#Status# CMV#U/U# 180# 10# 190#
Other# 308# 18# 326#
Total# 488# 28# 516#
Disease# Leukaemia# 244# 15# 259#
Other# 249# 14# 263#
Total# 493# 29# 522#
Mean#Age# 46.3#years# 46.4#years#
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3.3.8 Impact of genotype on overall survival  
The ten year overall survival of the patients is shown in Figure 3.15. Part (a) shows the entire 
cohort, and part (b) shows the patients with a CCTT genotype versus all other patients. There 
is a trend towards reduced overall survival in the CCTT group, but this is not statistically 




Figure 3.15 10 year overall survival for all patients, and split to show CCTT patients versus 
all others (95% confidence interval shown). Data suggest reduced overall survival in the 
CCTT genotype, but this does not reach significance. 
 
 
3.3.9 Impact of genotype on cumulative incidence of death due to GVHD 
Given that the literature would suggest that if excess deaths occur in the CCTT group, these 
should be due to GVHD, the cause of death was examined. For all patients, during the ten 
year post-transplant period, death due to GVHD occurs in approximately 11% of all patients, 
while overall mortality (from all causes) is approximately 52% Figure 3.16 (a). Prior to 
considering any potential effect from covariates, there appears to be little difference in risk for 
patients with the CCTT chimeric genotype in comparison to other genotypes, for cause of 
death other than GVHD (Figure 3.16 (b)). It appears, however, that the CCTT genotype 
confers a greater risk of death from GVHD than other genotypes. For comparison, the 
potential effect of risk factors known to impact on development of GVHD, T cell depletion 
and donor, are shown (Figure 3.16 (c) and (d)). These show minimal impact on risk of death 






Figure 3.16 Impact of genotype, T cell depletion and donor type on GVHD, and non-GVHD 
mortality. For the whole cohort approximately 10% of deaths are due to GVHD (a). For the 
CCTT genotype GVHD deaths rise to approximately 35% (b). Neither T cell depletion (c) nor 
donor type (d) impact on the proportion of deaths due to GVHD. 
 
To analyse this finding in more detail, a competing risks analysis was undertaken, taking into 
account CCTT genotype, and the other covariates shown in Table 3.3. The full model fitted 
includes CCTT and all covariates plus an interaction term for the most significant covariate 
(RIC, p=0.15) from the initial model (i.e. CCTT * RIC). The model effect p-values from the 
full model were used to inform a forward/backwards stepwise model selection procedure to 
find the final model, which minimised the increase in Bayesian Information criterion (delta 
BIC) over the null model, whilst ensuring that all model terms were significant. 
The final model (delta BIC= 2.627) for the effect of CCTT genotype on overall survival, 
death from GVHD, or death from causes other than GVHD contains only the term for CCTT 
(p= 0.021). No covariates were significant following the model selection procedure. Patients 
with a post-transplant chimeric SNP genotype of CCTT have a much greater risk of death 
from GVHD than the other genotypes (hazard ratio=2.53, 95% confidence interval=(1.149, 
5.571). This finding has potential clinical significance. While it is not practical to select 
donors to avoid a CCTT chimeric genotype, given the other factors that have to be taken into 




post-transplant care. This could include slower tapering of immunosuppression, or more 
aggressive up-front treatment should the patient develop GVHD. 
Finally, serum IL-22 concentration for a subset of these patients and donors was measured, to 
investigate whether the effect of genotype could be seen. The donors were analysed by the 
three potential genotypes, where samples were available (n=11). As with the other healthy 
controls, IL-22 was often undetectable, with a mean concentration of 4.4pg/ml. Given this, 




3.4  Discussion for Chapter Three 
 
The aim of this chapter was to explore the IL-22/IL-22R system in human HSCT.  I first 
examined the effect of transplant conditioning therapy (full and reduced intensity) on IL-22 
expression. In contrast to the mouse mode described by Hanash et al (Hanash et al., 2012), I 
found no evidence of IL-22 induction by reduced or full intensity conditioning in skin (by 
gene expression analysis) or serum (by ELISA), when looking at paired pre- and post-
conditioning samples. There are a number of potential reasons for this. The Hanash study was 
performed on serum and homogenised intestinal tissue two weeks post-transplant. It is, 
therefore, possible that the time point I had chosen was too early to see an effect. The reasons 
for choosing this early time point were in part that it limited other potentially confounding 
factors, and in part the difficulty of performing skin biopsies on patients (for research 
purposes only) at a later time, when platelet counts are likely to be lower and the patients feel 
less well. It is also possible that, although I did not see IL-22 induction in the serum, it would 
be present in the gut or liver, if it were possible to study these. It may be that the lack of IL-22 
induction observed is the result of different conditioning protocols used for mice and humans. 
This data, however, challenges the concept of conditioning-induced IL-22 providing a 
protective effect against subsequent GVHD development in humans.     
 
I have, however, shown evidence of elevated serum IL-22 in patients with GVHD when 
compared to healthy and post-transplant controls. One of the unanswered questions relating to 
the role of IL-22 in GVHD is whether it is exerting a protective or pathogenic response. This 
work has not enabled me to conclusively answer this question, however, Figure 3.9 illustrates 
that of the three patients with Grade II-IV aGVHD, in two the peak serum IL-22 occurs prior 
to the onset of clinically detectable GVHD. In addition, the gene expression data for healthy 
controls versus patients with GVHD shows significant upregulation of CXCL9 and CXCL10. 
I have not measured serum IFN, but my findings are consistent with those of Lamarthée et al, 
who demonstrated increased CXCL9 and CXCL10 expression in the presence of IL-22 wild 
type donor T cells, via phosphorylation of STAT 1, when compared to IL-22-/- T cells 
(Lamarthee et al., 2016a). These findings are suggestive of a pathological role for IL-22 in 
GVHD. 
  
In addition to the increase in IL-22, I have shown increased IL-22R expression in GVHD, 
both by gene expression analysis and immunohistochemistry. As has been previously 
discussed, inflammation is known to increase IL-22R expression in a number of experimental 
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models. The up-regulation of both IL-22 and IL-22R shown in this chapter may result in a 
positive feedback loop, where both the production and impact of IL-22 are increased. 
 
Finally, the impact of gene polymorphism for IL-22 has been investigated. These data are in 
keeping with the findings of previous murine models and data regarding high and low 
producer phenotypes at this SNP. Where the patient has a ‘low IL-22 producer’ phenotype, 
and the donor is a ‘high IL-22 producer’ there is a greater risk of death from GVHD. Several 
of the GVHD deaths in the CCTT cohort occur relatively late post-transplant (Figure 3.16 
(b)). This finding is consistent with what has previously been shown regarding the importance 
of donor-derived IL-22 in chronic cutaneous GVHD in a murine model (Gartlan et al., 2017). 
Unfortunately, serum samples were not available at the relevant time-point for the patients in 
the CCTT group who experienced late GVHD deaths, as it would have been interesting to 
investigate whether this associated with an elevated IL-22 concentration at that time. These 
late deaths raise the possibility that elevated IL-22 is to some extent responsible for driving 
the GVHD process, thus making it more resistant to treatment. The cohort studied here, and in 
particular the CCTT genotype group, was relatively small. Given the potential clinical 
implications of this finding, it would be interesting to repeat this study with a larger cohort. 
 
The major strength of this chapter is that multiple methods have been used to examine the role 
of the IL-22/IL-22R axis in GVHD. This has in some ways, however, also proved a weakness, 
in that to be able to perform the work, in the time frame available, it was necessary sometimes 
to use samples that were already available. This has meant that all the work has not been 
performed on the same cohort of patients, potentially introducing further variables. Were I to 
prospectively design this study, it would be beneficial to use the same methods, but to have a 
single cohort of patients, allowing for greater cross-referencing between findings.  
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Chapter 4 The effect of IL-22 on an in vitro model of graft versus host 
disease 
 
4.1  Introduction 
The therapeutic options for established GVHD remain limited and the search is on-going for 
agents that will treat GVHD while preserving the GVL effect (Wolf et al., 2012, Cassady et 
al., 2018). In this respect, the IL-22/IL-22R system represents an interesting target, as the 
absence of IL-22 receptors on leucocytes (Wolk et al., 2004) means that treatment would 
potentially directly target the affected tissues and not the donor lymphocytes.  
 
4.1.1 Targeting the IL-22/IL-22R system 
The differing impact of the IL-22/IL-22R system in different situations means that both 
enhancement and inhibition have been considered as therapeutic interventions. While many 
conditions would potentially benefit, those where research is currently more advanced are 
briefly discussed here. 
 
Two Phase I trials, NCT00563524 and NCT01010542, have evaluated the use of the anti-IL-
22 monoclonal antibodies ILV-094 and ILV-095 respectively, in the treatment of psoriasis. 
The first was unpublished, and the second terminated when it failed to meet the primary 
efficacy endpoint (Tsai and Tsai, 2017).  
 
F-652, a recombinant protein made of human IL-22 and human immunoglobulin G2-Fc, 
(Generon, (Shanghai) Corp. Ltd.) has been found to be safe and well-tolerated in Phase I trials 
(Tang et al., 2018), although eczematous lesions were seen at the injection site in a proportion 
of patients, when it was administered subcutaneously. Some ocular and cutaneous adverse 
events were reported at the higher intravenous doses tested, but there were no severe adverse 
events. A dose escalation study is currently recruiting to assess the safety and efficacy of the 
drug in patients with alcoholic hepatitis (NCT02655510). 
 
4.1.2 IL-22 as treatment for GVHD 
As discussed in Chapter 1.4.6, IL-22 given prophylactically in a murine model has already 
been shown to reduce GVHD morbidity from, and histological severity of, GVHD 
(Mertelsmann et al., 2013). A Phase II study looking the use of F-652, in patients with grade 
II-IV lower gastrointestinal graft versus host disease is currently in the recruitment phase 
(NCT02406651).  
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4.1.3 The skin explant model 
The skin explant model allows in vitro production of the histological changes seen in GVHD. 
Originally described by Vogelsang (Vogelsang et al., 1985), the classical model, where donor 
and recipient lymphocytes are initially cultured together and then co-cultured with skin from 
the transplant recipient, was shown to be predictive for the future development of GVHD 
post-transplant in T replete sibling transplants. In addition to being used clinically for GVHD 
prediction and modification of prophylaxis (Dickinson et al., 1999, Wang et al., 2006), the 
skin explant model has been used to dissect, in order to better understand, the biology of both 
GVHD and GVL. This has included the role of cytotoxic T lymphocytes in a minor 
histocompatibility mismatched model, demonstrating that minor histocompatibility antigens 
are a key target in GVHD (Dickinson et al., 2002) and the role of the Fas/Fas-ligand pathway, 
showing a correlation between higher grades of GVHD and increased epithelial Fas 
expression (Ruffin et al., 2011). Finally, it has been used to test potential agents that might 
reduce GVHD, for example IL-10 (Wang et al., 2002). 
 
4.1.4 Pathological GVHD grading 
The Lerner classification is used to describe the severity of pathological damage in tissues 
affected by GVHD and is distinct from clinical grading of GVHD (Lerner et al., 1974).The 
changes seen in target organs are assigned grades 0-IV. In the gastrointestinal tract, the 
grading is based on the presence or absence of mucosal glands and ‘denudation’ of the 
mucosa. In the liver the key feature is the percentage of abnormal bile ducts, as this was found 
to be more consistent than changes to the cells of the liver parenchyma. This study used 
models of cutaneous GVHD only, where the grading is as follows:  
Grade 0 Normal skin 
Grade I Vacuolisation of epidermal basal cells 
Grade II Diffuse vacuolisation of basal cells with dyskeratotic bodies 
Grade III Subepidermal cleft formation 




4.1.5 Questions for Chapter 4 
 
In this chapter I explored the hypothesis that IL-22 modifies the severity of GVHD using the 
skin explant model. This was achieved by adding IL-22 to the model, blocking endogenous 
IL-22 with antibodies and documenting the expression of IL-22R in the model. Specific 
questions addressed in this chapter are detailed below. 
 
1. Is IL-22 involved in pathological damage due to GVHD? 
 
2. Does IL-22 ameliorate pathological damage due to GVHD? 
 




1. To create a reproducible model of GVHD in a skin explant 
 
2. To explore the effect of the addition of differing concentrations of IL-22 to this model 
 




4.2  Methods for Chapter Four 
4.2.1 Sample collection 
Skin and blood samples in this chapter were collected as described in 2.2.1 and 3.2.1. 
 
4.2.2 Media and buffers 
Details of media and buffers used in this chapter are provided in Appendix 2. 
 
4.2.3 Mixed lymphocyte reaction 
A mixed lymphocyte reaction (MLR) was produced using peripheral blood from healthy 
donors. PBMCs were isolated from whole blood, collected in EDTA, as previously described. 
1x106 PBMCs from two healthy donors were suspended per 1ml of MLR culture medium 
(with human AB serum). These were cultured in 25 cm2 flasks (Cellstar) at 370 in a 
humidified, 5% CO2, 95% air incubator. After five days, the cultures were transferred to a 
universal container and centrifuged at 500g for 5 minutes. 50% of the supernatant was 
removed and frozen in 1ml aliquots at -800C (MLR D5). 50% of cells were also removed. The 
remaining cells were re-suspended in the remaining medium and cultured for a further two 
days. After a total of seven days culture they were transferred to a universal container, 
centrifuged at 500g for 5 minutes and the supernatant frozen in 1ml aliquots at -800C (MLR 
D7). 
 
4.2.4 The skin explant 
When using healthy control skin, 6mm punch biopsies were trimmed of excess dermis and cut 
into four pieces of equal size. Skin fragments were placed in different test conditions, further 
details of which are described with the results of each model, and incubated for 72 hours at 
370C, in a humidified, 5% CO2, 95% air incubator. Recombinant IL-22 (rIL-22) 
(ImmunoTools, Friesoythe), was reconstituted as per the manufacturer’s instructions, and 
stored at -800C in single use aliquots. The IL-22 monoclonal antibody (IL22JOP, Invitrogen, 
Thermo Fisher Scientific) was stored at 40C.  
 
4.2.5 Immunohistochemistry  
After 72 hours, biopsies from the skin explant model were fixed in 10% buffered formalin. 
Paraffin embedding, microtomy and haemotoxylin and eosin (H&E) staining were performed 
by the Newcastle Molecular Pathology Node.  Embedding and orientation were performed as 
per the clinical GVHD protocol.  
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4.2.6 Histopathological grading 
Assessment of the GVHD grade of the samples was performed blinded, by an independent 
assessor, with experience in GVHD grading. Assessment was made using the Lerner grading 
system, which grades from 0-IV (Lerner et al., 1974). 
 
4.2.7 Luminex  
Cytokine analysis of the MLR supernatants was performed using the ProcartaPlex® Multiplex 
Immunoassay (eBioscience). This uses magnetic bead technology to allow simultaneous 
detection of multiple protein targets. The assay was performed according to the 
manufacturer’s instructions, using 25µl of each sample. The plate was read using a Luminex 
200 and data analysed with ProcartaPlex Analyst version 1.0. Heatmaps were produced in 





4.3.1 Isolated effect of IL-22 on skin integrity in vitro 
Given my finding of elevated serum IL-22 in GVHD, I sought first to establish whether IL-22 
alone would act in a pro-inflammatory manner when added to a non-inflammatory system. 












This experiment was repeated three times (with three different skin donors). No evidence of 





Figure 4.1 Impact of increasing rIL-22 concentration on healthy skin. No evidence of 






























Figure 4.2 Examples of H&E stained sections at increasing concentrations of rIL-22. No 
difference in GVHD grade is shown at any concentration of IL-22. 
 
 
4.3.2 Anti IL-22 
Having established that rIL-22 alone, even at concentrations almost twice the highest I 
measured in the serum of patients with GVHD, did not cause histopathological evidence of 
skin damage, I next investigated the impact of an IL-22 blocking antibody. Four conditions 
were used for this experiment, again using 200µl of culture medium or MLR supernatant 















The concentration of anti-IL-22 required was calculated using the eBioscience Cytokine 
Neutralization protocol. For human IL-22 neutralisation, it is recommended that 1µg/ml of 
antibody is used to neutralise 0.2ng/ml of cytokine (http://diyhpl.us/~bryan/irc/protocol-
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online/protocol-cache/NU.htm#chart). When the IL-22 present in the MLR supernatant was 
neutralised, no improvement in, or worsening of, GVHD grade was observed (Figure 4.3). 
 
 
Figure 4.3 Impact of an IL-22 blocking antibody on MLR supernatant induced skin damage. 
No improvement in GVHD grade was observed when anti IL-22 was used to neutralise the 
IL-22 found in the MLR supernatant. Performed twice with different skin donors (red and 
blue). 
 
4.3.3 Ability of IL-22 to ameliorate supernatant-mediated GVHD reactions 
I next selected two concentrations of rIL-22 to test in a model where damage was induced 
using 200µl neat supernatant from an MLR reaction. The 30pg/ml concentration was in the 
range of the physiological concentration that I measured in the patients, while 150pg/ml was 
used as a supraphysiological level (only one patient had a serum IL-22 concentration higher 














As previously, skin in culture medium alone showed Grade I damage. The MLR supernatant 
reliably produced either Grade II or III damage. The addition of 30pg/ml of rIL-22 did not 
always have an effect, but where it did, this was always to increase the GVHD Grade. The 
addition of 150pg/ml rIL-22 resulted in resolution to Grade I in 50% of the experiments 
performed.  This response was comparable to that observed when 100µg/ml of 
methylprednisolone was added to a cellular, HLA mismatched explant model: 36% resolution 































Figure 4.4 Response in GVHD grade to the addition of 100µg/ml of methylprednisolone or 
cyclosporine A (CSA) to an HLA mismatched skin explant model. Methyprednisolone 
resulted in 36% resolution to Grade I, 21% to Grade II. No impact was seen with the addition 
of CSA. 
 
A summary of my results is shown in Figure 4.5. Part (a) shows the result of each individual 
skin/MLR pair. No improvement is seen with the addition of 30pg/ml, but with the addition of 
150pg/ml there was resolution to Grade I in half of the experiments performed. Wilcoxon 
matched-pairs for IL-22 30 vs IL-22 150, p=0.13. Part (b) shows these results combined 
(mean values with SEM). Parts (c) and (d) show the results colour-coded by skin and by MLR 
respectively. These illustrate that different outcomes are observed when different supernatants 
are paired with the same skin donor, and that the same supernatant can cause different 
outcomes when paired with a different skin donor. Examples of the H&E stained sections are 
shown in Figure 4.6. In the example showing MLR supernatant alone, in addition to the basal 
cell vacuolation that defines Grade II, there is evidence of severe epidermal damage. 
 
 















Figure 4.5 MLR supernatant reliably produced damage consistent with GVHD. The impact of 
differing concentrations of rIL-22 on this skin damage could then be assessed. (a) results of 
individual experiments with increasing concentrations of rIL-22, (b) mean values with SEM, 
(c) data colour coded by skin donor, (d) data colour coded by MLR supernatant. IL-22 30 
refers to the addition of 30pg/ml rIL-22, and IL-22 150 to 150pg/ml rIL-22. A reduction in 





















































































































Figure 4.6 Examples of H&E stained sections, showing the differing GVHD Grades. In 
addition to the criteria required to define the Grades, the MLR alone produces evidence of 
severe epidermal damage. 30pg/ml rIL-22 illustrates the subepidermal cleft formation of 
Grade III GVHD, while 150pg/ml rIL-22 shows vacuolisation only. 
 
 
Although the MLR supernatant used did not appear to influence the outcome, I next 
considered the effect of differences in baseline supernatant IL-22, and whether this might 
explain the separation of ‘responders’ from ‘non-responders’. Three different MLRs, with 
supernatant stored at two time points had been used in the model, giving the potential for 
different baseline IL-22 concentrations in the explant. The IL-22 concentration of each 
supernatant was therefore measured by ELISA, as described in 3.2.4 (data not shown). The 
baseline IL-22 concentration in the supernatants ranged from 8.5pg/ml to 123pg/ml. This 
difference alone, however, did not explain whether or not a response was observed. MLR2 D5 
and MLR2 D7, for example each resulted in one response and one non-response, when 
different skin donors were used. Interestingly, no response was observed with MLR1 D5, 
however, the supernatant with the lowest IL-22 concentration.  
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The cytokine content of each MLR supernatant was investigated using Luminex, and R was 
used to create heatmaps (work performed by A Resteu). Clustering was performed both by 
cytokine and by MLR. No pattern could be found to explain GVHD responders versus non-
responders. Examples of the heatmaps generated are shown in Figure 4.7. Perhaps the most 
interesting observation is the heterogeneity seen between MLRs. I was unable to find any 
pattern to explain why some samples responded to the addition of rIL-22 and others did not. 
 
 
Figure 4.7 Heatmaps demonstrating the heterogeneity of cytokine expression in the MLR 
supernatants. The cytokines measured are shown on the Y axes. a) MLR supernatants 
clustered by MLR, b) MLR supernatants clustered by log2 cytokines. No pattern could be 
found based on MLR cytokine content to explain GVHD responders versus non-responders 
when rIL-22 was added to the skin explant model. 
 
 
Baseline IL-22 and rIL-22 were then combined, to allow calculation of total IL-22 
concentration. Total IL-22 concentration in the MLR/MLR plus 30pg/ml IL-22 ranged from 
8.5-153pg/ml. Total IL-22 in the MLR plus 150pg/ml ranged from 158.5-273pg/ml (Figure 
4.8). Improvement in GVHD grade was only observed when the total IL-22 concentration was 




Figure 4.8 Impact on GVHD grade of combined baseline and rIL-22 concentration. 
Improvement in GVHD grade was only observed when the total IL-22 concentration was 
greater than 190pg/ml. 
 
 
The total IL-22 concentration in the MLR supernatant with or without 30pg/ml rIL-22 was in 
the same range as that measured in the serum of patients with GVHD, while the addition of 
150pg/ml rIL-22 resulted in a supra-physiological concentration. This raises the possibility of 
a biphasic response to IL-22, with a therapeutic effect only seen at concentrations above the 
physiological range. 
 
4.3.4 IL-22R in the skin explant model 
Finally, having seen an increase in IL-22R staining in pathological biopsies when compared 
to a healthy control (Figure 3.13), I investigated whether IL-22R was similarly increased in 
the skin explant model in order to explore the possibility that IL-22R induction might impact 
on which ‘patients’ responded to the addition of rIL-22. An additional slide was made, and 
stained for the IL-22R from the Control, MLR only and IL-22 150pg/ml blocks from 
experiment 4.3.3. The range of results was narrower than that seen with the patient biopsies 
(Figure 4.9). No significant difference in percentage of IL-22R positive cells was seen 
between responders and non-responders (two way ANOVA), although this may be due to the 
small sample size. There is a trend towards increased IL-22R staining in the responder group 




Figure 4.9 IL-22R staining in the skin explant model. No significant difference is seen 



































4.4  Discussion for Chapter Four 
 
The aim of this chapter was to explore the potential for therapeutic use of IL-22 in an in vitro 
model. This work has demonstrated that the addition of rIL-22 alone to healthy skin cultured 
in vitro does not cause GVHD-type skin damage, even when added at supra-physiological 
concentrations. In a non-inflammatory model, no effect was seen with the addition of rIL-22. 
In contrast to the worsening symptoms seen in IBD (Li et al., 2014) in the preliminary 
experiments performed with an IL-22 blocking antibody, no change in GVHD grade has been 
observed. 
 
In the inflammatory model that was created using the MLR supernatant, however, the 
addition of rIL-22 did have an effect. A trend towards a pro-inflammatory effect was seen 
with the addition of a low concentration of rIL-22, and a reduction in GVHD grade at higher 
concentrations, although neither reached statistical significance. It was interesting to observe 
that no benefit was achieved until IL-22 concentrations were higher than those measured in 
the serum of patients with aGVHD. This raises the possibility of a biphasic response to IL-22, 
with a therapeutic effect only seen above the physiological range. 
 
Interrogation of the cytokine content of the MLR supernatants did not reveal a ‘responder’ 
phenotype to explain why some experiments did, and some did not, respond to the addition of 
rIL-22. Although numbers are very small, the trend towards higher IL-22R staining seen in 
the ‘responder’ experiments suggests up-regulation of the IL-22R, and thus up-regulation of 
the IL-22/IL-22R system may contribute to the response. This observation warrants further 
investigation, due to the potential clinical impact of being able to predict which patients 
would respond to treatment with IL-22. 
 
Taken together these results suggest that, in this model, IL-22 is not required for GVHD, and 
that IL-22 alone does not cause GVHD. When added to an inflammatory system with the 
potential for causing GVHD, however, a biphasic response is seen, where IL-22 is pro-
inflammatory at low concentrations and anti-inflammatory at high concentrations. Increased 
IL-22R staining in responders would be consistent with a theory of increased activation of the 
IL-22/IL-22R system being required to produce an anti-inflammatory effect. 
 
The major benefit of the skin explant model is the ability to perform multiple reproductions of 
the same experiment. The MLR supernatant, in particular, reliably produced a minimum of 
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Grade II GVHD, in contrast to the use of true patient/donor pairs, where not all experiments 
result in GVHD (Wang et al., 2006). In addition, the model combines multiple factors, giving 
a ‘read-out’ that is comparable to a genuine clinical finding. While the experiments are 
performed in vitro, it also has the benefit of being a human model. 
 
The limitations include the fact that the Lerner criteria are relatively blunt, with only five 
potential Grades of GVHD. This means that some of the finer differences between samples 
were lost. In addition, due to the avascular nature of the experiment, there is no ability to 
recruit additional effector cells etc., so it is possible that some potential effects that would be 
observed in vivo are not seen.  
 
Given the synergistic effect that has been demonstrated in a murine model between donor 
derived IL-22, and type I interferon, resulting in increased STAT1 phosphorylation and 
GVHD severity (Lamarthee et al., 2016a), it would be interesting to investigate whether at 
higher concentrations of IL-22, this pathway becomes ‘saturated’, with a return towards 
proportionally increased STAT3 phosphorylation. I would propose that future work should 
include investigation of the relative phosphorylation of the STAT1 versus STAT3 pathway, 
with differing concentrations of IL-22. I would also propose further exploration of changes in 
gene expression, to assess whether there is a phenotype that predicts for either response or 
non-response to rIL-22. This could be further developed for other treatments (e.g. 
corticosteroids) to explore whether it is a generic ‘response’ phenotype. 
 
Finally, it would be interesting to repeat these studies in a gut explant model. In two murine 
models (Hanash et al., 2012, Mertelsmann et al., 2013) the effects of IL-22 inhibition or 
supplementation were seen in the liver and intestine, but not the skin. It may be that it is 
possible to demonstrate a more significant response to IL-22 in a human gut than a human 
skin model. To my knowledge, there is currently no validated human intestinal explant model 
for the investigation of GVHD. The Phase I study currently underway at Memorial Sloane 






Chapter 5 General Discussion, Conclusions and Future Work 
 
GVHD remains a limiting factor in the use of HSCT in a clinical setting, both as a result of 
direct morbidity and mortality and because the difficulty in separating GVHD from GVL 
means we are not able to harness the full effect of the donor immune system. This thesis 
began with the hypothesis that recipient ILC3-derived IL-22 protects target organs from 
GVHD by protecting the recipient’s tissues from conditioning induced damage, resulting in 
reduced T cell activation. The main aims were to further clarify the role of recipient and 
donor ILCs and IL-22 in a human transplant setting, especially given the known contrasting 
effects of IL-22, in order to develop a clearer understanding of their potential therapeutic use.  
 
For ILC-derived IL-22 to play a role in human GVHD requires the presence of IL-22-
secreting ILC in the blood and ideally the target organs of GVHD. I have demonstrated that 
ILCs are reduced, and in many cases eradicated from the peripheral blood by transplant 
conditioning, and that by Day 28 post HSCT they are predominantly of donor origin. Given 
the importance of Alemtuzumab as a method of T cell depletion in the United Kingdom, 
having demonstrated CD52 expression on ILCs, consistent with the finding of Gross et al 
(Gross et al., 2016), it was interesting to observe the difference in circulating ILC recovery 
between those patients who did and those who did not receive Alemtuzumab.  
 
As discussed, I was unable to accurately subset ILCs in the early post-transplant period, due 
to the very small number of cells circulating at this time. When investigating the role of ILC 
recovery on IL-22 production, I have therefore had to use total ILC numbers as a proxy for 
ILC3 (IL-22 producing) recovery. Taking this into account, however, I have found no 
correlation between ILC recovery and serum IL-22 concentration. The size of the population 
does, however, suggest that ILC3s are unlikely to play a major role in GVHD. I have not 
found evidence of a difference in (donor) ILC recovery between patients who did and did not 
develop Grade II-IV aGVHD. There are many potential reasons for this. ILC recovery (at 
least total ILC recovery) may not impact on GVHD development. It may be that circulating 
ILCs do not impact on GVHD development, but in target organs their recovery is important, 
although it is worth noting that I have not found evidence for an increase in the number of 
ILCs in the skin of patients with GVHD. Nor have I been able to show that ILCs are 
responsible for the production of IL-22 in this setting. It may be that any difference is masked 
by confounding factors, such as the use of Alemtuzumab, or the presence of viral reactivation. 
Given the effect of Alemtuzumab, the proposed impact of lymphopenia on IL-7, and ILC 
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dependence on IL-7, the impact of IL-7 concentration on ILC recovery and aGVHD was 
investigated. I found no correlation between IL-7 concentration and ILC recovery. Nor did I 
find that early IL-7 concentration post HSCT correlated with subsequent aGVHD 
development, in contrast to previously published data (Dean et al 2008). I propose differences 
that might have been seen in my cohort have been masked by the effect of Alemtuzumab on 
IL-7. 
 
In relation to the initial hypothesis regarding the role of IL-22 in HSCT, I have found no 
evidence that IL-22 is induced, in either the skin or the blood, by transplant conditioning, 
regardless of intensity. It remains possible, however, that transplant conditioning induces 
local IL-22 production in either the gut or liver. One of the most surprising findings of this 
project, was the absence of change in gene expression seen in the skin with reduced intensity 
conditioning. Although the Ferrara three-phase model of GVHD development is based on full 
intensity conditioning (Ferrara et al., 2009), it has been presumed that similar mechanisms are 
responsible for GVHD in reduced intensity conditioning. I believe my data challenge both the 
concept of IL-22 being induced by conditioning and subsequently protecting target organs 
from aGVHD, and that the three-phase model is the mechanism behind GVHD development 
in reduced intensity conditioning. 
 
I have, however, shown that serum IL-22 is increased in patients with GVHD and 
demonstrated increased IL-22R expression in the skin of patients with GVHD, suggesting 
involvement of the IL-22-IL-22R system. I have not been able to conclusively demonstrate 
whether IL-22 plays a pathological or protective role in aGVHD. A number of observations, 
however, lend weight to it playing a pathological role at physiological levels. The first of 
these is that peak serum IL-22 appeared to precede the development of clinically apparent 
aGVHD in a number of cases, although there may be a time lag between the onset of 
development of GVHD in the target organs and the appearance of clinical features. There may 
also be a delay in the patient presenting to a physician and the development of GVHD being 
recorded. Secondly, the up-regulation of CXCL9, CXCL10 and STAT1 in the gene 
expression profiling of skin biopsies from patients with aGVHD when compared to healthy 
controls is consistent with the findings of Lamarthée et al, (Lamarthee et al., 2016a) who 
demonstrated the importance of IL-22 in this system in a mouse model. Finally, in a skin 
explant model, IL-22 concentrations in the range that I had measured in the serum of patients 
with GVHD were associated with the presence of histological changes consistent with 
aGVHD, and the addition of low dose IL-22 was associated with a trend towards increasing 
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GVHD Grade. IL-22 does not, however, appear to be necessary for the development of 
aGVHD. Not all of the patients with aGVHD had elevated serum IL-22 concentrations, and 
preliminary results using an IL-22 blocking antibody in the skin explant model would support 
this finding. 
 
Further data to support the importance of IL-22 in the development of GVHD came from the 
SNP study. Published data on high and low IL-22 producing phenotypes (De Luca et al., 
2013), with the results of a number of murine IL-22 knockout models (Hanash et al., 2012, 
Mertelsmann et al., 2013, Couturier et al., 2013, Lamarthee et al., 2016a), would predict that a 
low IL-22 producer recipient with a high IL-22 producer donor (a CCTT genotype at 
rs2227485) would result in excess GVHD deaths. This was the finding of a competing risks 
analysis of 524 patient-donor pairs, comparing a CCTT genotype with all other patients 
combined. 
 
It was not until IL-22 concentrations reached supraphysiological levels in the skin explant 
model that a reduction in the grade of GVHD was seen. This would suggest, taken with the 
additional findings above, that if IL-22 has potential as therapy for aGVHD, this will be at 
supraphysiological concentrations. Given the lack of alternative treatments available for 
steroid refractory GVHD, and the potential for treating the target organs without targeting the 
lymphocytes, further investigation is warranted. Careful consideration would, however, need 
to be given to the pharmacodynamics and pharmacokinetic properties of any drug, given the 
potentially detrimental properties at lower concentrations. It will be interesting to observe the 
outcomes of the current trial of F-562 in patients with lower gastrointestinal GVHD 
(NCT02406651). 
 
In addition to the difficulties posed by the small cell numbers, I think the biggest limitation of 
this project is the heterogeneity of transplant patients. Patients begin conditioning therapy 
having been treated for different diseases, with varying protocols and for different time 
periods. Transplant protocols themselves vary, depending on disease, donor, graft source and 
age of patient. Post-transplant complications and treatment required for these vary widely. In 
contrast to this heterogeneity, however, GVHD represents a stereotypic response to immune 
effector cell injury. One potential method for overcoming the heterogeneity, to investigate 
ILC reconstitution only, would be to look in an autologous setting. As graft versus host 
disease was a central theme of this project, all the work was performed on samples from 
patients receiving allogeneic transplants. The autologous setting would, however, offer a 
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potentially much more homogenous patient and treatment cohort. For example, patients with 
multiple myeloma receiving a first autologous SCT have usually been treated with a limited 
number of induction regimens, and standardly receive single agent melphalan as conditioning 
(Auner et al., 2018). In addition, the fact that these patients do not usually develop GVHD or 
viral reactivation means that the first 100 days post transplant is also much more homogenous 
than that of a patient post allograft. My data would suggest that the absence of T cell 
depletion from this regimen is likely to result in more rapid ILC reconstitution, and 
potentially combining this patient cohort with an alternative method of detection such as 
CyTOF, would enable further investigation of the kinetics of different ILC subset recovery. 
 
This work has, perhaps, raised as many questions as it has answered, and there are many 
aspects that warrant further investigation. One is further analysis of the gene expression data 
in both conditioning and GVHD, using gene pathway analysis to further explore up- versus 
down-regulation in both settings. Following on from this, a potentially fruitful avenue of 
exploration is further investigation of the downstream pathway of IL-22, in particular the 
relative phosphorylation of STAT1 versus STAT3 in GVHD, and whether this is altered by 
the IL-22 concentration. This could be undertaken using a combination of clinical samples, 
and the skin explant model. A better understanding of the impact of IL-22 on this pathway in 
GVHD would be beneficial to our ability to use this pathway as a therapeutic target. 
 
A further variable in the IL-22 pathway not addressed in this project is IL-22BP. The binding 
protein is an inhibitor of IL-22 as it prevents binding to the trans-membrane receptor. While I 
have shown a rise in IL-22 in the serum in GVHD, it would be interesting to investigate 
whether this is mirrored by a fall in IL-22BP (as seen in the DSS model of colitis) or a rise (as 
seen in humans with IBD). IL-22BP represents another potential target for modulation of the 
IL-22/IL-22R system, but the normal response in GVHD needs first to be established. To my 
knowledge, only one group has published data on IL-22BP in the context of GVHD (Lounder 
et al., 2018). The study investigated IL-22 levels in children with gastrointestinal GVHD. An 
inverse correlation between IL-22 and IL-22BP levels at Day 30 was shown, but not an 
association with gastrointestinal GVHD. No further information regarding IL-22BP is given. 
 
Finally, this project was performed using peripheral blood and skin samples, in part because 
of all the organs affected by GVHD, skin is the least invasive to sample. It is possible, 
however, that the IL-22-IL-22R axis plays a bigger role in gut or liver GVHD, as has been 
suggested in two murine models (Hanash et al., 2012, Mertelsmann et al., 2013). It would be 
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interesting to investigate whether this finding translates into human GVHD, by investigating 
ILC composition, IL-22R staining and IL-22 concentration in other target organs. The biggest 
difficulty that I would envisage in undertaking this work would be access to pathological 
samples. In our institution, a limited number of sigmoid colon biopsies and very few liver 
biopsies are performed each year. A validated gut or liver GVHD explant model would 
potentially enable work on the impact of the therapeutic use of IL-22 in this setting. 
 
Despite many recent advances in the field of haemato-oncology, allogeneic stem cell 
transplant remains the only curative option for a number of haematological conditions, and 
GVHD continues to pose a significant barrier to successful outcomes. Targeting of the IL-
22/IL-22R system provides an exciting option for the future, but further knowledge of the 
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